{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:01:59Z","timestamp":1788904919204,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd006257","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000}}],"reference-count":688,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006257.pub2","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T07:37:20Z","timestamp":1714376240000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease"],"prefix":"10.1002","volume":"2024","author":[{"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine; Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"},{"name":"College of Medicine and Public Health; Flinders University; Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0001|cit1","first-page":"114A","article-title":"Effects of a calcium channel antagonist versus an ACE inhibitor on diabetic nephropathy [abstract no: S1064]","volume":"9","author":"Estacio","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0002|cit2","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23 Suppl 2","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0004|cit4","first-page":"146A","article-title":"Aggressive lowering of blood pressure in normotensive type 2 diabetic patients: beneficial effects on stroke, progression of retinopathy and nephropathy [abstract no: A0763]","volume":"12","author":"Estacio","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0197-2456(95)00154-9","article-title":"Baseline characteristics of participants in the Appropriate Blood pressure Control in Diabetes trial","volume":"17","author":"Estacio","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"9B","key":"10.1002\/14651858.CD006257.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-9149(98)00750-4","article-title":"Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial","volume":"82","author":"Estacio","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.CIR.0000049640.46039.52","article-title":"Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes","volume":"107","author":"Mehler","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2337\/diacare.19.11.1243","article-title":"Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM","volume":"19","author":"Savage","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0009|cit9","article-title":"The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes","volume":"Doc No 104","author":"Savage","year":"1993","journal-title":"Online Journal of Current Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s001250050629","article-title":"Appropriate Blood pressure Control in NIDDM (ABCD) trial","volume":"39","author":"Schrier","year":"1996","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0272-6386(12)70236-6","article-title":"Appropriate Blood Pressure Control in type II diabetes (ABCD Trial): implications for complications","volume":"20","author":"Schrier","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0026-0495(99)90121-X","article-title":"Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus","volume":"48","author":"Stabler","year":"1999","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.amjhyper.2006.05.011","article-title":"Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes","volume":"19","author":"Estacio","year":"2006","journal-title":"American Journal of Hypertension"},{"issue":"Oct","key":"10.1002\/14651858.CD006257.pub2-BIB0015|cit15","first-page":"568A","article-title":"Aggressive blood pressure control with valsartan in normotensive type 2 diabetic patients results in regression of albuminuria [abstract no: SU-PO165]","volume":"15","author":"Estacio","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1291\/hypres.30.929","article-title":"Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy","volume":"30","author":"Abe","year":"2007","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2337\/diacare.20.10.1576","article-title":"Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria","volume":"20","author":"Ahmad","year":"1997","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0168-8227(03)00016-0","article-title":"Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects","volume":"60","author":"Ahmad","year":"2003","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJM199608223350814","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Apperloo","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0020|cit20","first-page":"597","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Curren","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00019053-200220010-00004","article-title":"Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation","volume":"20","author":"Hogan","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0022|cit22","first-page":"S63","article-title":"Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"63","author":"Locatelli","year":"1997","journal-title":"Kidney International - Supplement"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1046\/j.1523-1755.2000.07507.x","article-title":"The role of underlying nephropathy in the progression of renal disease","volume":"75","author":"Locatelli","year":"2000","journal-title":"Kidney International - Supplement"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0024|cit24","first-page":"S39","article-title":"Perspectives of ACE inhibition in progressive renal failure [abstract no: 104]","volume":"3","author":"Mann","year":"1997","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0025|cit25","unstructured":"Maschio G Alberti D Janin G Locatelli F Mann J Motolese M The use of benazepril in the treatment of progressive renal disease [abstract] 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 65"},{"issue":"15","key":"10.1002\/14651858.CD006257.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00005344-199900001-00004","article-title":"Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group","volume":"33 Suppl 1","author":"Maschio","year":"1999","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0028|cit28","first-page":"597","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Maschio","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"41","key":"10.1002\/14651858.CD006257.pub2-BIB0029|cit29","first-page":"5798","article-title":"Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril","volume":"158","author":"Pedersen","year":"1996","journal-title":"Ugeskrift for Laeger"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0030|cit30","first-page":"S159","article-title":"Economic evaluation of benazepril in chronic renal insufficiency","volume":"63","author":"Hout","year":"1997","journal-title":"Kidney International - Supplement"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0031|cit31","unstructured":"AMADEO: A trial to compare telmisartan 40mg titrated to 80mg versus losartan 100mg in hypertensive type-2 diabetic patients with overt nephropathy The Protection Trial Programme - Micardis Protection 2005"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0033|cit33","first-page":"A159","article-title":"Influence of glycaemic control on proteinuria in patients with type 2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial [abstract no: 0601-P]","volume":"56","author":"Bakris","year":"2007","journal-title":"Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2215\/CJN.06960712","article-title":"Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy","volume":"8","author":"Moranne","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0035|cit35","first-page":"73A","article-title":"Predictors of aldosterone breakthrough with ARB treatment in diabetic nephropathy [abstract no: F-FC315]","volume":"20","author":"Moranne","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0036|cit36","first-page":"391","article-title":"Angiotensin receptor blockers and microalbuminuria in hypertensive patients with early (microalbuminuric) stage diabetic nephropathy","volume":"1","author":"Arai","year":"2008","journal-title":"Molecular Medicine Reports"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0037|cit37","first-page":"894-9","article-title":"A comparative study of efficacy of enalapril versus telmisartan in patients with diabetic nephropathy","volume":"10","author":"Arpitha","year":"2020","journal-title":"National Journal of Physiology, Pharmacy & Pharmacology"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2337\/diacare.23.12.1823","article-title":"Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial","volume":"23","author":"O'Hare","year":"2000","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF02850049","article-title":"Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes","volume":"23","author":"Atmaca","year":"2006","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/1056-8727(94)90003-5","article-title":"ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects","volume":"8","author":"Bakris","year":"1994","journal-title":"Journal of Diabetes & its Complications"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0041|cit41","first-page":"110","article-title":"Short term effects of maximum tolerable doses of ACE-inhibitor (lisinopril), angiotensin receptor blocker (losartan) and add-on losartan on proteinuria and glomerular filtration rate [abstract]","volume":"14","author":"Bansal","year":"2004","journal-title":"Indian Journal of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0042|cit42","unstructured":"Bansal R Agarwal SK Study of maximum tolerable doses of ACE-I (lisinopril), ARB (losartan) and add-on ARB on proteinuria and progression of renal disease in patients of type 2 diabetes with early nephropathy: results of one year follow up [abstract no: CNO-9] 36th Annual Conference of the Indian Society of Nephrology (ISNCON 2005); 2005 Dec 1-3; Cochin, India 2005 34"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0272-6386(12)70256-1","article-title":"A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy","volume":"20","author":"Bauer","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0044|cit44","first-page":"115","article-title":"Long term use of captopril or nifedipine in normotensive microalbuminuric patients with insulin-dependent diabetes mellitus","volume":"23","author":"Bilo","year":"1993","journal-title":"Diabetes Research"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0045|cit45","first-page":"331","article-title":"Captopril or nifedipine in normotensive microalbuminuric IDDM patients [abstract no: 85P]","volume":"3","author":"Bilo","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2337\/diacare.24.5.919","article-title":"Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes","volume":"24","author":"Bojestig","year":"2001","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0047|cit47","first-page":"A87","article-title":"Role of candesartan, lisinopril and their combination on blood pressure and albuminuria in hypertensive microalbuminuric diabetic subjects [abstract no: 84]","volume":"5","author":"Cooper","year":"2000","journal-title":"Nephrology"},{"issue":"7274","key":"10.1002\/14651858.CD006257.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3317\/jraas.2003.019","article-title":"Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design","volume":"4","author":"Andersen","year":"2003","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","article-title":"Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study","volume":"28","author":"Andersen","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ajh.2007.2","article-title":"Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis","volume":"21","author":"Knudsen","year":"2008","journal-title":"American Journal of Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/BF00577736","article-title":"Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study","volume":"72","author":"Capek","year":"1994","journal-title":"Clinical Investigator"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1681\/ASN.V34s97","article-title":"A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group","volume":"3","author":"Bain","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0054|cit54","first-page":"301","article-title":"Predictors of the rate of progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy [abstract no: 38P]","volume":"4","author":"Breyer","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ki.1996.481","article-title":"Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group","volume":"50","author":"Breyer","year":"1996","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0056|cit56","first-page":"S156","article-title":"Angiotensin converting enzyme inhibition in diabetic nephropathy. The Collaborative Study Group","volume":"45","author":"Breyer","year":"1994","journal-title":"Kidney International - Supplement"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/ki.1994.469","article-title":"Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group","volume":"46","author":"Hebert","year":"1994","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0058|cit58","unstructured":"Lewis EJ Bain R Hunsicker LG Collaborative Study Group A controlled clinical trial of angiotensin-converting enzyme inhibition in type 1 diabetic nephropathy [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 424"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0059|cit59","first-page":"305","article-title":"A controlled clinical trial of angiotensin-converting enzyme (ACE) inhibition in type 1 diabetic nephropathy [abstract no: 39P]","volume":"4","author":"Lewis","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"20","key":"10.1002\/14651858.CD006257.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0061|cit61","unstructured":"Lewis EJ The captopril trial [abstract] 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 66"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0062|cit62","first-page":"382","article-title":"An economic analysis of captopril in the treatment of diabetic nephropathy [abstract no: 16P]","volume":"5","author":"Rodby","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0063|cit63","first-page":"308","article-title":"The urine protein to creatinine ratio (p\/c) as a predictor of 24 hour urine protein excretion (24up) in type 1 diabetics with nephropathy [abstract]","volume":"4","author":"Rodby","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/0272-6386(95)90054-3","article-title":"The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group","volume":"26","author":"Rodby","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1523-1755.1998.00982.x","article-title":"Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group","volume":"54","author":"Weiss","year":"1998","journal-title":"Kidney International"},{"issue":"5-6","key":"10.1002\/14651858.CD006257.pub2-BIB0066|cit66","first-page":"305","article-title":"The effects of a low-dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients","volume":"30","author":"Carella","year":"1999","journal-title":"Journal of Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0067|cit67","first-page":"127A","article-title":"Comparison of losartan vs enalapril in type 2 diabetes mellitus patients with diabetic nephropathy [abstract no: A0652]","volume":"10","author":"Castelao","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0068|cit68","first-page":"ii285","article-title":"A combination treatment of an angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker can inhibit plasma renin-angiotensin system more completely and persistently as compared with high or moderate dose angiotensin-receptor blocker treatments in type 2 diabetic nephropathy: nested cohort study of candesartan-trandolapril trial in diabetic CKD (CAT Trial) [abstract no: MP156]","volume":"1","author":"Nakao","year":"2008","journal-title":"NDT Plus"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0069|cit69","first-page":"284","article-title":"Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial","volume":"25","author":"Chase","year":"1993","journal-title":"Annals of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.amjms.2018.01.017","article-title":"Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy","volume":"355","author":"Chen","year":"2018","journal-title":"American Journal of the Medical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02550409","article-title":"Comparison of captopril and enalapril in the treatment of hypertension in patients with non-insulin dependent diabetes mellitus and nephropathy","volume":"22","author":"Cheng","year":"1990","journal-title":"International Urology & Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0072|cit72","first-page":"433","article-title":"Does captopril reduce proteinuria in normotensive, non-azotaemic diabetic patients? [abstract]","volume":"4","author":"Cocchi","year":"1989","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1681\/ASN.V1061253","article-title":"Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group","volume":"10","author":"Cordonnier","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0074|cit74","first-page":"110A","article-title":"Renal interstital expansion is modified by perindopril in true diabetic glomerulosclerosis (DG) in type 2 (NIDDM) diabetic patients. a 2 years sequential biopsy study [abstract no: A0522]","volume":"8","author":"Cordonnier","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0075|cit75","first-page":"A89","article-title":"Renal interstitial expansion is modified by perindopril in true diabetic glomerulosclerosis (DG) in type 2 (NIDDM) diabetic patients. A 2 years sequential biopsy study [abstract]","volume":"12","author":"Cordonnier","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0076|cit76","first-page":"A30","article-title":"Blockade of the renin-angiotensin system attenuates renal TGF-b gene expression and activity in human diabetic nephropathy [abstract no: M-PO20058]","volume":"10","author":"Langham","year":"2005","journal-title":"Nephrology"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006257.pub2-BIB0077|cit77","first-page":"167A","article-title":"Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition [abstract no: F-PO529]","volume":"13","author":"Langham","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.2337\/dc06-0911","article-title":"Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition","volume":"29","author":"Langham","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/diacare.21.1.104","article-title":"Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM","volume":"21","author":"Crepaldi","year":"1998","journal-title":"Diabetes Care"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006257.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1681\/ASN.2005121326","article-title":"Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial","volume":"17","author":"Barnett","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"19","key":"10.1002\/14651858.CD006257.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0082|cit82","unstructured":"DETAIL: Diabetics exposed to telmisartan and enalapril [brochure] The Protection Trial Programme - Micardis Protection 2005 20"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1056-8727(01)00165-9","article-title":"Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study [Erratum in: N Engl J Med. 2005 Apr 21;352(16)1731]","volume":"16","author":"Rippin","year":"2002","journal-title":"Journal of Diabetes & its Complications"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0084|cit84","first-page":"98","article-title":"Effects of ACE inhibition and angiotension II receptor blockade on glomerular basement membrane protein excretion and change selectivity in type 2 diabetic patients","volume":"7","author":"Deyneli","year":"2006","journal-title":"JRAAS - Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2337\/dc06-0255","article-title":"Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study","volume":"29","author":"Azizi","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-2456(00)00060-X","article-title":"The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group","volume":"21","author":"Lievre","year":"2000","journal-title":"Controlled Clinical Trials"},{"issue":"7438","key":"10.1002\/14651858.CD006257.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","article-title":"Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)","volume":"328","author":"Marre","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0088|cit88","unstructured":"Marre M Lievre M Chatellier G Vasmant D Mann J Passa P Low-dose ramipril (1.25 mg\/day) does not decrease cardiovascular events in type 2 diabetes patients with microalbuminuria\/proteinuria: the DIABHYCAR (type 2 DIABetes, HYpertension, CArdiovascular events and Ramipril) study [abstract no: 185] 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1-5; Budapest, Hungary 2002"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0089|cit89","first-page":"B40","article-title":"Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa","volume":"23 Suppl 2","author":"Marre","year":"2000","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s001250050631","article-title":"The DIAB-HYCAR Study","volume":"39","author":"Passa","year":"1996","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2337\/diacare.26.3.855","article-title":"Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study","volume":"26","author":"Vaur","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0092|cit92","first-page":"S93","article-title":"AVP gene variants, plasma copeptin and nephropathy in type 2 diabetes [abstract no: 183]","volume":"61","author":"Velho","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2298\/VSP0305555D","article-title":"Efficacy of valsartan in the treatment of persistent microalbuminuria in normotensive patients with type 1 diabetes","volume":"60","author":"Dragovic","year":"2003","journal-title":"Vojnosanitetski Pregled"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2298\/JMH0501021D","article-title":"Effect of AT1 receptor blockers on plasma lipid profiles in type 1 diabetic patients with incipient diabetic nephropathy","volume":"24","author":"Dragovic","year":"2005","journal-title":"Jugoslovenska Medicinska Biohemija"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0095|cit95","first-page":"158A","article-title":"The Diovan Reduction Of Proteinutria (DROP) study: albuminuria response to high-doses of valsartan in type 2 diabetes mellitus [abstract no: TH-PO244]","volume":"17","author":"Hollenberg","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0b013e328277596e","article-title":"Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus","volume":"25","author":"Hollenberg","year":"2007","journal-title":"Journal of Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/HJH.0b013e32834a8a25","article-title":"Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients","volume":"29","author":"Weir","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/HJH.0b013e328332bd61","article-title":"Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria","volume":"28","author":"Weir","year":"2010","journal-title":"Journal of Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0099|cit99","first-page":"1319","article-title":"Microalbuminuria in insulin-dependent diabetics: the prevention of diabetic nephropathy","volume":"118","author":"Durruty","year":"1990","journal-title":"Revista Medica de Chile"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0100|cit100","first-page":"1036","article-title":"Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor","volume":"124","author":"Durruty","year":"1996","journal-title":"Revista Medica de Chile"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2337\/diabetes.50.4.843","article-title":"Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT)","volume":"50","year":"2001","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0102|cit102","first-page":"99","article-title":"A pilot, multicentre, randomized, double-blind, parallel study evaluating the efficacy and tolerability of enalapril, nifedipine retard and placebo on the evolution of diabetic nephropathy in normotensive, insulin-dependent diabetic patients with increased urinary albumin excretion","volume":"5","author":"Viberti","year":"1992","journal-title":"Journal of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.2337\/diabetes.51.10.3083","article-title":"Podocyte number in normotensive type 1 diabetic patients with albuminuria","volume":"51","author":"White","year":"2002","journal-title":"Diabetes"},{"issue":"9095","key":"10.1002\/14651858.CD006257.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0105|cit105","first-page":"1357","article-title":"Renal effect of lisinopril in insulin dependent diabetes mellitus (IDDM) without hypertension [abstract no: A0560]","volume":"7","author":"Fuller","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2337\/diabetes.47.9.1507","article-title":"Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. EURODIAB Controlled Trial of Lisinopril in IDDM","volume":"47","author":"Penno","year":"1998","journal-title":"Diabetes"},{"issue":"9068","key":"10.1002\/14651858.CD006257.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1046\/j.1365-2362.2002.01011.x","article-title":"Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients","volume":"32","author":"Schalkwijk","year":"2002","journal-title":"European Journal of Clinical Investigation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0109|cit109","first-page":"847A","article-title":"Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients [abstract no: A4431]","volume":"12","author":"Schalkwijk","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0110|cit110","first-page":"949","article-title":"Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus","volume":"161","author":"Sjolie","year":"1999","journal-title":"Ugeskrift for Laeger"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0111|cit111","first-page":"632","article-title":"FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial","volume":"18","author":"Kim","year":"2017","journal-title":"Trials [Electronic Resource]"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0112|cit112","first-page":"2008-17","article-title":"The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial","volume":"45","author":"Yoo","year":"2022","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"18","key":"10.1002\/14651858.CD006257.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1517\/14656566.2013.848195","article-title":"Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria","volume":"14","author":"Fogari","year":"2013","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0114|cit114","first-page":"33","article-title":"Renal and retinal changes after treatment with ramipril and pentoxifyline in subjects with IDDM","volume":"30","author":"Garg","year":"1998","journal-title":"Annals of Ophthalmology - Glaucoma"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF00403306","article-title":"Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group","volume":"39","year":"1996","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0116|cit116","first-page":"485","article-title":"Effects of captopril on ambulatory blood pressure, renal and cardiac function in microalbuminuric type 1 diabetic patients","volume":"20","author":"Hansen","year":"1994","journal-title":"Diabete et Metabolisme"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0117|cit117","first-page":"336","article-title":"Captopril (C) delays progression to overt renal disease in insulin-dependent diabetes mellitus (IDDM) patients with microalbuminuria [abstract]","volume":"3","author":"Mogensen","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group","volume":"271","author":"Viberti","year":"1994","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0119|cit119","unstructured":"Viberti G European Microalbuminuria Captopril Study Group (EMCSG) The effect of captopril on the progression of microalbuminuria in insulin-dependent diabetes [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 424"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0120|cit120","first-page":"385","article-title":"Secondary prevention of diabetic nephropathy by captopril in patients with insulin-dependent diabetes mellitus (IDDM) and microalbuminuria [abstract]","volume":"5","author":"Viberti","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0121|cit121","first-page":"450","article-title":"Long-term effect of captopril on kidney function in normotensive insulin dependent diabetic patients (IDDM) with diabetic nephropathy [abstract no: 444]","volume":"6","author":"Hommel","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9200","key":"10.1002\/14651858.CD006257.pub2-BIB0122|cit122","first-page":"253","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [Erratum appears in Lancet 2000 Sep 2;356(9232):860]","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/diacare.19.11.1225","article-title":"Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation","volume":"19","author":"Gerstein","year":"1996","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00125-005-1858-4","article-title":"The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis","volume":"48","author":"Gerstein","year":"2005","journal-title":"Diabetologia"},{"issue":"117","key":"10.1002\/14651858.CD006257.pub2-BIB0125|cit125","first-page":"8","article-title":"Diabetes and the HOPE study: implications for macrovascular and microvascular disease","author":"Gerstein","year":"2001","journal-title":"International Journal of Clinical Practice. Supplement"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3949\/ccjm.67.4.287","article-title":"The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not","volume":"67","author":"Hoogwerf","year":"2000","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.CIR.0000050600.49419.25","article-title":"Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study","volume":"107","author":"Lamy","year":"2003","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006257.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"291A","DOI":"10.1016\/S0735-1097(02)81305-5","article-title":"Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients [abstract no:1051-29]","volume":"39","author":"Lonn","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/01.hjr.0000106836.977722.cf","article-title":"Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients","volume":"10","author":"Lonn","year":"2003","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006257.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"290A","DOI":"10.1016\/S0735-1097(02)81304-3","article-title":"Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial [abstract no: 1051-28]","volume":"39","author":"Lonn","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2337\/diacare.25.11.1919","article-title":"Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy","volume":"25","author":"Lonn","year":"2002","journal-title":"Diabetes Care"},{"issue":"Sept","key":"10.1002\/14651858.CD006257.pub2-BIB0132|cit132","first-page":"156A","article-title":"Renal insufficiency (RI) as predicator of cardiovascular (CV) outcomes and impact of ramipril: the HOPE study [abstract no: A0836]","volume":"11","author":"Mann","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ajkd.2003.07.015","article-title":"Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study","volume":"42","author":"Mann","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.ASN.0000051594.21922.99","article-title":"Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study","volume":"14","author":"Mann","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1523-1755.2004.00513.x","article-title":"Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study","volume":"65","author":"Mann","year":"2004","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CNP63181","article-title":"Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study","volume":"63","author":"Mann","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD006257.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/hc3901.096700","article-title":"Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril","volume":"104","author":"Mathew","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00365510500236366","article-title":"The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences","volume":"240","author":"McQueen","year":"2005","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation Supplement"},{"issue":"9299","key":"10.1002\/14651858.CD006257.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0140-6736(01)07186-0","article-title":"Blood-pressure reduction and cardiovascular risk in HOPE study","volume":"358","author":"Sleight","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.0000044940.65226.1F","article-title":"Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study","volume":"107","author":"Smieja","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0142|cit142","first-page":"127","article-title":"The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators","volume":"12","year":"1996","journal-title":"Canadian Journal of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD006257.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1161\/01.CIR.0000038890.39298.8D","article-title":"Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events","volume":"106","author":"Veres","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM200001203420302","article-title":"Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0145|cit145","first-page":"145","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [Erratum in: 2000 May 4;342(18):1376; Erratum in: N Engl J Med 2000 Mar 9;342(10):748]","volume":"342","author":"Yusuf","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjcard.2004.04.028","article-title":"Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy","volume":"94","author":"Aguilar","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2004.10.019","article-title":"Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy","volume":"45","author":"Atkins","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006257.pub2-BIB0148|cit148","first-page":"7A","article-title":"Effect of baseline proteinuria and change in proteinuria with treatment on the risk of renal endpoints in the Irbesartan Diabetic Nephropathy Trial (IDNT) [abstract no: F-FC033]","volume":"13","author":"Atkins","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006257.pub2-BIB0149|cit149","first-page":"A3","article-title":"A clinical trial in patients with overt type 2 diabetic nephropathy [abstract no: 11]","volume":"7","author":"Atkins","year":"2002","journal-title":"Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1681\/ASN.2004090763","article-title":"Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial","volume":"16","author":"Berl","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0152|cit152","first-page":"5","article-title":"Impact of baseline and achieved blood pressure on cardiovascular events (CV) in type 2 diabetic nephropathy [abstract no: F-FC023]","volume":"14","author":"Berl","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/j.ajkd.2006.07.009","article-title":"The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension","volume":"48","author":"Busch","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0154|cit154","first-page":"c291","article-title":"Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension","volume":"108","author":"Busch","year":"2008","journal-title":"Nephron"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.clinthera.2007.07.029","article-title":"Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective","volume":"29","author":"Coyle","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0156|cit156","first-page":"158","article-title":"Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: Post-hoc analysis of the Irbesartan Diabetic Nephropathy Trial [abstract no: P405]","volume":"26","author":"Evans","year":"2009","journal-title":"Diabetic Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/ndt\/gfr696","article-title":"Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial","volume":"27","author":"Evans","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1523-1755.2005.00456.x","article-title":"C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy","volume":"68","author":"Friedman","year":"2005","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1681\/ASN.2004100846","article-title":"Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy","volume":"16","author":"Friedman","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.2012.74","article-title":"Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers","volume":"82","author":"Lambers Heerspink","year":"2012","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0161|cit161","first-page":"663A","article-title":"Both hypokalemia and hyperkalemia predict cardiovascular risk during blood pressure lowering therapy in patients with diabetes and nephropathy [abstract no: SA-PO2407]","volume":"21","author":"Lambers Heerspink","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2013.09.016","article-title":"Estimated GFR decline as a surrogate end point for kidney failure: A post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)","volume":"63","author":"Lambers Heerspink","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006257.pub2-BIB0163|cit163","first-page":"S158","article-title":"Blood pressure-independent nephroprotection by irbesartan - results of the IDNT study [abstract no: V3-1]","volume":"126","author":"Lewis","year":"2001","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0165|cit165","first-page":"220A","article-title":"A clinical trial in patients with overt type 2 diabetic nephropathy [abstract no: A1138]","volume":"12","author":"Lewis","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1053\/ajkd.2001.27442","article-title":"A clinical trial in type 2 diabetic nephropathy","volume":"38","author":"Lewis","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"10 (Pt 2)","key":"10.1002\/14651858.CD006257.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0895-7061(02)03007-8","article-title":"The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes","volume":"15","author":"Lewis","year":"2002","journal-title":"American Journal of Hypertension"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0168|cit168","first-page":"193A","article-title":"Irbesartan is projected to be cost and life saving in the USA for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria [abstract no F-PO603]","volume":"14","author":"Palmer","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.jhh.1001729","article-title":"An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting","volume":"18","author":"Palmer","year":"2004","journal-title":"Journal of Human Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/ndt\/gfg232","article-title":"An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings","volume":"18","author":"Palmer","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0171|cit171","first-page":"178A","article-title":"Irbesartan diabetic nephropathy trial (IDNT), a multicenter collaborative trial of angiotensin II receptor antagonism on renal function, mortality, and morbidity in hypertensive type 2 diabetic patients with nephropathy [abstract no: A0910]","volume":"10","author":"Pohl","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2004110919","article-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations","volume":"16","author":"Pohl","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/S0149-2918(03)80208-4","article-title":"The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy","volume":"25","author":"Rodby","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ndt\/15.4.487","article-title":"The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group","volume":"15","author":"Rodby","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.ajkd.2015.03.032","article-title":"Serum bicarbonate and kidney disease progression and cardiovascular outcome in patients with diabetic nephropathy: a post hoc analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)","volume":"66","author":"Schutte","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/HJH.0b013e32835200f9","article-title":"An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials","volume":"30","author":"Smink","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006257.pub2-BIB0177|cit177","first-page":"769A","article-title":"The relationship between total proteinuria, albuminuria, and the signs and symptoms of nephrotic syndrome in diabetic kidney disease [abstract no: SU-PO832]","volume":"18","author":"Stoycheff","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0178|cit178","unstructured":"INNOVATION: Incipient to overt: angiotensin II receptor blocker, telmisartan, investigation on type II diabetic nephropathy The Protection Trial Programme - Micardis Protection 2005"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0179|cit179","first-page":"158A","article-title":"Incipient to overt: angiotensin II blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study [abstract no: TH-PO243]","volume":"17","author":"Makino","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1291\/hypres.31.657","article-title":"Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of the Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study","volume":"31","author":"Makino","year":"2008","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes","volume":"30","author":"Makino","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/147323000503300610","article-title":"The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study","volume":"33","author":"Makino","year":"2005","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0183|cit183","first-page":"451","article-title":"INNOVATION study","volume":"68 Suppl 9","author":"Ogawa","year":"2010","journal-title":"Nippon Rinsho - Japanese Journal of Clinical Medicine"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0184|cit184","first-page":"6A","article-title":"Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria [abstract no: F-FC025]","volume":"14","author":"Andersen","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.2337\/diacare.26.12.3296","article-title":"Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria","volume":"26","author":"Andersen","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2369-11-29","article-title":"Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria","volume":"11","author":"Andersen","year":"2010","journal-title":"BMC Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2337\/dc10-2214","article-title":"Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy","volume":"34","author":"Broedbaek","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.clinthera.2007.07.029","article-title":"Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective","volume":"29","author":"Coyle","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/ndt\/gfr102","article-title":"Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial","volume":"26","author":"Engelen","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.2337\/dc11-0324","article-title":"Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial","volume":"34","author":"Hellemons","year":"2011","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006257.pub2-BIB0191|cit191","first-page":"S158","article-title":"Irbesartan in patients with type 2 diabetes mellitus and microalbuminura (IRMA 2) [abstract]","volume":"126","author":"Lehnert","year":"2001","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3317\/jraas.2004.031","article-title":"How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics","volume":"5","author":"Llewelyn","year":"2004","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0193|cit193","first-page":"193A","article-title":"Irbesartan is projected to be cost and life saving in the USA for treatment of patients with Type 2 diabetes, hypertension, and microalbuminuria [abstract no: F-PO603]","volume":"14","author":"Palmer","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"40","key":"10.1002\/14651858.CD006257.pub2-BIB0194|cit194","first-page":"5519","article-title":"Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"163","author":"Parving","year":"2001","journal-title":"Ugeskrift for Laeger"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0196|cit196","first-page":"162A","article-title":"Impact of arterial blood pressure on development of diabetic nephropathy at different systolic blood pressure levels in patients with type 2 diabetes and persistent microalbuminuria: an IRMA 2 substudy [abstract no: TH-PO263]","volume":"17","author":"Persson","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0197|cit197","first-page":"635A","article-title":"Impact of new biomarkers on development of diabetic nephropathy in the irbesartan in patients with type 2 diabetes and microalbuminuria (IRMA 2) study [abstract no: SA-PO356]","volume":"16","author":"Persson","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.2337\/db06-0827","article-title":"Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy","volume":"55","author":"Persson","year":"2006","journal-title":"Diabetes"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0199|cit199","first-page":"635A","article-title":"The effect of irbesartan treatment on vascular biomarkers in patients with type 2 diabetes and microalbuminuria. An irbesartan in patients with type 2 diabetes and microalbuminuria (IRMA 2) substudy [abstract no: SA-PO357]","volume":"16","author":"Persson","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/00365510802187226","article-title":"Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study","volume":"68","author":"Persson","year":"2008","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006257.pub2-BIB0201|cit201","first-page":"338A","article-title":"N-terminal pro brain natriuretic peptide (NTproBNP) in the irbesartan in patients with type 2 diabetes and microalbuminuria study. An IRMA 2 substudy [abstract no: TH-PO1006]","volume":"19","author":"Persson","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"e14405","DOI":"10.1111\/dme.14405","article-title":"Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: an IRMA2 sub-study","volume":"38","author":"Piazza","year":"2021","journal-title":"Diabetic Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-8227(01)00289-3","article-title":"Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM)","volume":"55","author":"Katayama","year":"2002","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0272-6386(05)80003-4","article-title":"Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria","volume":"37","author":"Jerums","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/j.1523-1755.2005.00359.x","article-title":"Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes","volume":"67","author":"Thomas","year":"2005","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1464-5491.2004.01316.x","article-title":"Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria","volume":"21","author":"Jerums","year":"2004","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-8227(02)00102-X","article-title":"The effects of losartan and fosinopril in hypertensive type 2 diabetic patients","volume":"58","author":"Kavgaci","year":"2002","journal-title":"Diabetes Research & Clinical Practice"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0208|cit208","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120973502","article-title":"Renal outcomes of treatment with telmisartan in patients with stage 3\u20134 chronic kidney disease: a prospective, randomized, controlled trial (JINNAGA)","volume":"8","author":"Kitamura","year":"2020","journal-title":"SAGE Open Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02849886","article-title":"Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril","volume":"22","author":"Ko","year":"2005","journal-title":"Advances in Therapy"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0210|cit210","first-page":"611","article-title":"Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy","volume":"92","author":"Krairittichai","year":"2009","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1523-1755.2000.00224.x","article-title":"Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy","volume":"58","author":"Lacourciere","year":"2000","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF00403306","article-title":"Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group","volume":"39","year":"1996","journal-title":"Diabetologia"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0213|cit213","first-page":"304","article-title":"Captopril decreases the rate of progression of renal disease in normotensive, insulin-dependent diabetes mellitus (IDDM) patients with microalbuminuria [abstract]","volume":"4","author":"Laffel","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0002-9343(99)80226-5","article-title":"The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group","volume":"99","author":"Laffel","year":"1995","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF00918480","article-title":"Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy","volume":"228","author":"Larsen","year":"1990","journal-title":"Graefes Archive for Clinical & Experimental Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0216|cit216","first-page":"335","article-title":"Enalapril slows the progressioin of renal disease in non-insulin dependent diabetes mellitus (NIDDM): results of a 3-yr multicenter, randomized, prospective, double-blind study [abstract]","volume":"3","author":"Lebovitz","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0217|cit217","first-page":"S150","article-title":"Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria","volume":"45","author":"Lebovitz","year":"1994","journal-title":"Kidney International - Supplement"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0218|cit218","unstructured":"Lee S Kim TY Lim JS Kim HK Lee JW Prospective study of effect of converting enzyme inhibitor, captopril, on renal function and proteinuria in diabetic nephropathy [abstract] 11th International Congress of Nephrology 1990 160A"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0219|cit219","first-page":"S379","article-title":"A follow-up study of the course of nephropathy in type I diabetes mellitus [abstract no: P1222]","volume":"3","author":"Lewis","year":"1997","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0272-6386(99)70036-3","article-title":"Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group","volume":"34","author":"Lewis","year":"1999","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0221|cit221","first-page":"382","article-title":"Design and baseline characteristics of the study of the effect of intensity of blood pressure (BP) management on the progression of type 1 diabetic nephropathy [abstract]","volume":"5","author":"Rodby","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1681\/ASN.V5101775","article-title":"The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group","volume":"5","author":"Rodby","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0223|cit223","first-page":"30","article-title":"Beneficial effects of angiotensin-converting enzyme inhibitors on cardiovascular and renal functions in patients with hypertension and diabetes","volume":"11","author":"Lin","year":"1995","journal-title":"Acta Cardiologica Sinica"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0224|cit224","first-page":"446","article-title":"Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO)","volume":"24","author":"Maione","year":"2007","journal-title":"Giornale Italiano di Nefrologia"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0225|cit225","first-page":"646","article-title":"Protocol of the long-term impact of RAS inhibition on cardiorenal outcomes (LIRICO) randomized trial","volume":"20","author":"Maione","year":"2007","journal-title":"Journal of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1681\/ASN.2018040443","article-title":"The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): a randomized, controlled trial","volume":"29","author":"Saglimbene","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0227|cit227","first-page":"103","article-title":"ACE inhibitor, ARB, or combined therapy in patients with diabetes and microalbuminuria: the long-term impact of RAS inhibition on cardiorenal outcomes (LIRICO) randomized clinical trial [abstract no: SA-OR115]","volume":"28","author":"Strippoli","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6656","key":"10.1002\/14651858.CD006257.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.297.6656.1092","article-title":"Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria","volume":"297","author":"Marre","year":"1988","journal-title":"BMJ"},{"issue":"6585","key":"10.1002\/14651858.CD006257.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/bmj.294.6585.1448","article-title":"Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria","volume":"294","author":"Marre","year":"1987","journal-title":"British Medical Journal Clinical Research Ed"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0891-6632(90)90042-4","article-title":"Microalbuminuria and ACE inhibition in non-hypertensive diabetics","volume":"4","author":"Marre","year":"1990","journal-title":"Journal of Diabetic Complications"},{"issue":"2-3","key":"10.1002\/14651858.CD006257.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0891-6632(91)90029-O","article-title":"Recent advance in the treatment of diabetic nephropathy: angiotensin I converting enzyme (ACE) inhibitors","volume":"5","author":"Marre","year":"1991","journal-title":"Journal of Diabetic Complications"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0232|cit232","first-page":"377","article-title":"Effect of different antihypertensive agents in normotensive microalbuminuric patients with IDDM and NIDDM [abstract no: 16P]","volume":"5","author":"Gilbert","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0233|cit233","first-page":"1270","article-title":"Effects of different antihypertensive agents in normotensive microalbuminuric type I and type II diabetic patients [abstract]","volume":"45","author":"Allen","year":"1994","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0234|cit234","unstructured":"Melbourne Diabetic Nephropathy Study Group Cooper ME Allen T Jerums G DeLuise M Alford F Effects of different antihypertensive agents in normotensive microalbuminuric type I and type II diabetic patients [abstract] 12th International Congress of Nephrology 1993 424"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006257.pub2-BIB0236|cit236","first-page":"28A","article-title":"Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]","volume":"19","author":"Mehdi","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0237|cit237","first-page":"623A","article-title":"Mechanism of hyperkalemia during combined renin angiotensin aldosterone system (RAAS) blockade in diabetic nephropathy [abstract no: SA-PO2246]","volume":"20","author":"Mehdi","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0238|cit238","first-page":"539","article-title":"Validation of a systems biology derived urinary metabolite panel for prediction of albuminuria response to spironolactone therapy in type 2 diabetes [abstract no: FR-PO461]","volume":"29","author":"Mulder","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"A81","DOI":"10.1053\/j.ajkd.2012.02.272","article-title":"Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]","volume":"59","author":"Srivastava","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/jim-2016-000102","article-title":"Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy","volume":"64","author":"Srivastava","year":"2016","journal-title":"Journal of Investigative Medicine"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0241|cit241","first-page":"908A","article-title":"Combined blockade with the renin-angiotensin-aldosterone system to improve outcomes in diabetics with nephropathy (DN) [abstract no: PUB582]","volume":"16","author":"Toto","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2215\/CJN.07460713","article-title":"Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy","volume":"9","author":"Van Buren","year":"2014","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0243|cit243","first-page":"432","article-title":"Achieving blood pressure goals in high risk patients with diabetic nephropathy [abstract no: 272]","volume":"58","author":"Van Buren","year":"2010","journal-title":"Journal of Investigative Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2310\/JIM.0b013e3181ff46a5","article-title":"Effective antihypertensive strategies for high-risk patients with diabetic nephropathy","volume":"58","author":"Van Buren","year":"2010","journal-title":"Journal of Investigative Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1742-1241.1999.tb11811.x","article-title":"The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy","volume":"53","author":"Cheung","year":"1999","journal-title":"International Journal of Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0011-393X(99)90003-6","article-title":"The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial","volume":"60","author":"Muirhead","year":"1999","journal-title":"Current Therapeutic Research, Clinical & Experimental"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s101570200023","article-title":"Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes","volume":"6","author":"Nakamura","year":"2002","journal-title":"Clinical & Experimental Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000045773","article-title":"Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy","volume":"86","author":"Nakamura","year":"2000","journal-title":"Nephron"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000316707","article-title":"Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy","volume":"33","author":"Nakamura","year":"2010","journal-title":"Kidney & Blood Pressure Research"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0026-0495(98)90364-X","article-title":"Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study","volume":"47","author":"Nankervis","year":"1998","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0251|cit251","first-page":"229","article-title":"The effect of benazepril in treatment of the patients with early diabetic nephropathy with normotensive and microalbuminuria","volume":"8","author":"Niu","year":"2008","journal-title":"China Tropical Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0252|cit252","first-page":"327","article-title":"Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy","volume":"7","author":"O'Donnell","year":"1993","journal-title":"Journal of Human Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1291\/hypres.30.325","article-title":"Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy","volume":"30","author":"Ogawa","year":"2007","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","article-title":"Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies","volume":"10","author":"Anderson","year":"2011","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2215\/CJN.06640712","article-title":"Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures","volume":"8","author":"Barzilay","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: The ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/dc11-0545","article-title":"Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study","volume":"34","author":"Barzilay","year":"2011","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCULATIONAHA.109.864199","article-title":"Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/TRANSCEND) Trials","volume":"121","author":"Bohm","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ahj.2013.04.016","article-title":"Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease","volume":"166","author":"Bohm","year":"2013","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.diabres.2008.12.005","article-title":"Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET\/TRANSCEND research programme","volume":"83","author":"Cukierman-Yaffe","year":"2009","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"e13694","DOI":"10.1371\/journal.pone.0013694","article-title":"In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events","volume":"5","author":"Dans","year":"2010","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"23","key":"10.1002\/14651858.CD006257.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1161\/CIRCULATIONAHA.112.103234","article-title":"Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries","volume":"126","author":"Dehghan","year":"2012","journal-title":"Circulation"},{"issue":"18","key":"10.1002\/14651858.CD006257.pub2-BIB0264|cit264","first-page":"1682","article-title":"Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus","volume":"173","author":"Dunkler","year":"2013","journal-title":"JAMA Internal Medicine"},{"issue":"9655","key":"10.1002\/14651858.CD006257.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)61860-7","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Gallieni","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/2047487313510678","article-title":"The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial","volume":"21","author":"Heerspink","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.111.086660","article-title":"Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)","volume":"126","author":"Kappert","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.111.086660","article-title":"Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)","volume":"126","author":"Kappert","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00392-013-0644-4","article-title":"Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET\/TRANSCEND","volume":"103","author":"Lonn","year":"2014","journal-title":"Clinical Research in Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/HYPERTENSIONAHA.112.199562","article-title":"Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)","volume":"60","author":"Mancia","year":"2012","journal-title":"Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/HJH.0000000000002567","article-title":"Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials","volume":"38","author":"Mancia","year":"2020","journal-title":"Journal of Hypertension"},{"issue":"16","key":"10.1002\/14651858.CD006257.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/CIRCULATIONAHA.110.008870","article-title":"Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)","volume":"124","author":"Mancia","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/HJH.0b013e32835bf7b0","article-title":"Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial","volume":"31","author":"Mann","year":"2013","journal-title":"Journal of Hypertension"},{"issue":"9638","key":"10.1002\/14651858.CD006257.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006257.pub2-BIB0275|cit275","first-page":"48A","article-title":"Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk: results from the ONTARGET trial [abstract no: F-FC209]","volume":"19","author":"Mann","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9655","key":"10.1002\/14651858.CD006257.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(08)61863-2","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Narayanan","year":"2008","journal-title":"Lancet"},{"issue":"9655","key":"10.1002\/14651858.CD006257.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)61861-9","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Nonoguchi","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","article-title":"Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)","volume":"59","author":"Redon","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0279|cit279","first-page":"1","article-title":"Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme","volume":"3","author":"Ruilope","year":"2007","journal-title":"Vascular Health & Risk Management"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006257.pub2-BIB0280|cit280","first-page":"309A","article-title":"ONTARGET: cardiovascular outcome in patients at high cardiovascular risk and with chronic kidney disease (CKD) [abstract no: TH-PO886]","volume":"19","author":"Schmieder","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0281|cit281","first-page":"707A","article-title":"A gene variant in the CERS2 gene is associated with worsening albuminuria in diabetic patients of ON TARGET and TRANSCEND [abstract no: SA-PO351]","volume":"24","author":"Shiffman","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/HJH.0b013e32832d7370","article-title":"Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study","volume":"27","author":"Sleight","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.hjh.0000357905.78704.9a","article-title":"Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor","volume":"27","author":"Sleight","year":"2009","journal-title":"Journal of Hypertension - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","article-title":"Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials","volume":"148","author":"Teo","year":"2004","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/HJH.0b013e3283522a51","article-title":"Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies","volume":"30","author":"Verdecchia","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"14","key":"10.1002\/14651858.CD006257.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.109.865774","article-title":"Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease","volume":"120","author":"Verdecchia","year":"2009","journal-title":"Circulation"},{"issue":"9655","key":"10.1002\/14651858.CD006257.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(08)61862-0","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Wetzels","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0289|cit289","first-page":"1763","article-title":"Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data","volume":"124","author":"Yu","journal-title":"Chinese Medical Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006257.pub2-BIB0290|cit290","first-page":"iii416","article-title":"Impact of olmesartan with or without ace inhibitor on renal and cardiovascular protection in type 2 diabetes with overt proteinuria [abstract no: Su322]","volume":"3","author":"Imai","year":"2010","journal-title":"NDT Plus"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0291|cit291","first-page":"72A","article-title":"Olmesartan reduces incidence of end stage diabetic nephropathy trial: ORIENT study [abstract no: F-FC313]","volume":"20","author":"Imai","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0293|cit293","unstructured":"Imai E Chan JCN Ito S Haneda M Mankino H Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetic patients with overt nephropathy [abstract no: SA764] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/ndt\/gft249","article-title":"Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria)","volume":"28","author":"Imai","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006257.pub2-BIB0295|cit295","first-page":"ii13","article-title":"Proteinuria is a therapeutic target for renoprotection in patients with type 2 diabetes with overt nephropathy: A sub-analysis of ORIENT study [abstract no: FO027]","volume":"27","author":"Imai","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/hr.2013.86","article-title":"Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension)","volume":"36","author":"Imai","year":"2013","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1291\/hypres.29.703","article-title":"Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design","volume":"29","author":"Imai","year":"2006","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/ndt\/gfv272","article-title":"Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure)","volume":"31","author":"Imai","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0299|cit299","first-page":"527","article-title":"Importance of eGFR change as a surrogate end point of ESRD in a randomized controlled trial [abstract no: FR-PO490]","volume":"28","author":"Kanda","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6698","key":"10.1002\/14651858.CD006257.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bmj.299.6698.533","article-title":"Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy","volume":"299","author":"Parving","year":"1989","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1523-1755.2001.00790.x","article-title":"Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients","volume":"60","author":"Parving","year":"2001","journal-title":"Kidney International"},{"issue":"4A","key":"10.1002\/14651858.CD006257.pub2-BIB0302|cit302","first-page":"58","article-title":"Diabetic microalbuminuria and cilazapril","volume":"94","author":"Phillips","year":"1993","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2796.2001.00821.x","article-title":"Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomized study","volume":"249","author":"Poulsen","year":"2001","journal-title":"Journal of Internal Medicine"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD006257.pub2-BIB0304|cit304","first-page":"123","article-title":"Early ACE-i intervention in microalbuminuric patients with type 1 diabetes: effects on albumin excretion, 24 h ambulatory blood pressure, and renal function","volume":"27","author":"Poulsen","year":"2001","journal-title":"Diabetes & Metabolism"},{"issue":"18","key":"10.1002\/14651858.CD006257.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1161\/01.STR.0000155731.92786.e9","article-title":"Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria","volume":"36","author":"Asselbergs","year":"2005","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.atherosclerosis.2006.11.011","article-title":"Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects","volume":"196","author":"Asselbergs","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0308|cit308","first-page":"36A","article-title":"Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]","volume":"16","author":"Atthobari","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clinthera.2006.03.012","article-title":"Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)","volume":"28","author":"Atthobari","year":"2006","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0310|cit310","first-page":"71A","article-title":"The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]","volume":"16","author":"Atthobari","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1093\/ndt\/gfl244","article-title":"The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study","volume":"21","author":"Atthobari","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/ndt\/gfm091","article-title":"Impact of weight change on albuminuria in the general population","volume":"22","author":"Bello","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ahj.2011.03.028","article-title":"Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT)","volume":"161","author":"Brouwers","year":"2011","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfz266","article-title":"Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study","volume":"36","author":"De Jong","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0002-9149(00)01042-0","article-title":"Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT])","volume":"86","author":"Diercks","year":"2000","journal-title":"American Journal of Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD006257.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/eurheartj\/ehi253","article-title":"Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial","volume":"26","author":"Geluk","year":"2005","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jac\/dks419","article-title":"Effect of pravastatin and fosinopril on recurrent urinary tract infections","volume":"68","author":"Pouwels","year":"2013","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.HYP.0000244082.26293.2d","article-title":"Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients","volume":"48","author":"de Wal","year":"2006","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3317\/jraas.2007.029","article-title":"Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects","volume":"8","author":"de Wal","year":"2007","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2008.02.108","article-title":"Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria","volume":"102","author":"Harst","year":"2008","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","article-title":"Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial","volume":"61","author":"Fernandez Juarez","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.2215\/CJN.00910113","article-title":"25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system","volume":"8","author":"Fernandez-Juarez","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/nep.12781","article-title":"High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy","volume":"22","author":"Fernandez-Juarez","year":"2017","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006257.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"iii478","DOI":"10.1093\/ndt\/gfv191.20","article-title":"Circulating TNF receptor levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin angiotensin system [abstract no: SP300]","volume":"30","author":"Fernandez-Juarez","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0325|cit325","first-page":"201A","article-title":"Vitamin D levels and renal progression in type 2 diabetic patients with blockade of the renin angiotensin system [abstract no: TH-PO438]","volume":"24","author":"Luno","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0326|cit326","first-page":"12A","article-title":"Effect of dual blockade of renin angiotensin system on the progression of type 2 diabetic nephropathy [abstract no: TH-OR051]","volume":"22","author":"Luno","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0327|cit327","first-page":"1056-62","article-title":"Comparative study of the renal effect of telmisartan and ramipril in patients with hypertension and type 2 diabetes mellitus","volume":"12","author":"Raj","year":"2021","journal-title":"Journal of Cardiovascular Disease Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0328|cit328","first-page":"6","article-title":"Long-term effect of enalapril on normotensive type II diabetes mellitus","volume":"119","author":"Ravid","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.1996.00440030080010","article-title":"Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study","volume":"156","author":"Ravid","year":"1996","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ki.1995.135","article-title":"Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors","volume":"47","author":"Ravid","year":"1995","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","article-title":"Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients","volume":"118","author":"Ravid","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0332|cit332","first-page":"S161","article-title":"Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II","volume":"45","author":"Ravid","year":"1994","journal-title":"Kidney International - Supplement"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2337\/diacare.26.5.1402","article-title":"Analysis of metabolic parameters as predictors of risk in the RENAAL study","volume":"26","author":"Appel","year":"2003","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1002\/14651858.CD006257.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study","volume":"163","author":"Bakris","year":"2003","journal-title":"Archives of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1007\/s00125-005-1893-1","article-title":"Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study","volume":"48","author":"Boner","year":"2005","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3317\/jraas.2000.062","article-title":"The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)","volume":"1","author":"Brenner","year":"2000","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0338|cit338","first-page":"613","article-title":"Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective","volume":"20","author":"Burgess","year":"2004","journal-title":"Canadian Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00019053-200624060-00003","article-title":"The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy","volume":"24","author":"Carides","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.amjcard.2005.07.061","article-title":"Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies","volume":"96","author":"Carr","year":"2005","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2337\/diacare.27.4.874","article-title":"Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study","volume":"27","author":"Chan","year":"2004","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"A406","DOI":"10.1016\/S1098-3015(10)75007-5","article-title":"Pharmacoeconomic consequences of losartan therapy in patiens undergoing diabetic end-stage renal disease [abstract]","volume":"12","author":"Citarella","year":"2009","journal-title":"Value in Health"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0343|cit343","first-page":"160A","article-title":"Quality of life in persons with NIDDM and nephropathy at baseline: the losartan renal protection study (RENAAL) [abstract no: A0823]","volume":"10","author":"Dasbach","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/HJH.0b013e328014953c","article-title":"Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies","volume":"25","author":"Eijkelkamp","year":"2007","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2840-1-2","article-title":"Losartan and diabetic nephrology: commentaries on the RENAAL study","volume":"1","author":"Fisman","year":"2002","journal-title":"Cardiovascular Diabetology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1046\/j.1523-1755.62.s82.14.x","article-title":"Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union","volume":"82","author":"Gerth","year":"2002","journal-title":"Kidney International - Supplement"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006257.pub2-BIB0348|cit348","first-page":"699a","article-title":"Losartan reduced the burden of ESRD: public health implications from the RENAAL study for Latin America [abstract no: PUB143]","volume":"13","author":"Gerth","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0349|cit349","first-page":"208A","article-title":"Losartan reduces the costs associated with ESRD: the RENAAL study economic evaluation [abstract no: A1078]","volume":"12","author":"Herman","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.26.3.683","article-title":"Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation","volume":"26","author":"Herman","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney International"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006257.pub2-BIB0352|cit352","first-page":"249a","article-title":"The RENAAL ESRD risk score: a risk score system for predicting end stage renal disease in patients with type 2 diabetes and nephropathy [abstract no: F-PO925]","volume":"13","author":"Keane","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","article-title":"The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study","volume":"63","author":"Keane","year":"2003","journal-title":"Kidney International"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006257.pub2-BIB0354|cit354","first-page":"264a","article-title":"The impact of losartan on the lifetime incidence of end-stage renal disease and associated costs: lifetime projections based on the RENAAL study [abstract no: F-P1000]","volume":"13","author":"Keane","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2215\/CJN.01381005","article-title":"Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL Study","volume":"1","author":"Keane","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-006-0427-6","article-title":"Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study","volume":"10","author":"Kurokawa","year":"2006","journal-title":"Clinical & Experimental Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/qjmed\/94.2.89","article-title":"Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus","volume":"94","author":"Kvetny","year":"2001","journal-title":"QJM"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.2012.74","article-title":"Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers","volume":"82","author":"Lambers Heerspink","year":"2012","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0359|cit359","first-page":"663A","article-title":"Both hypokalemia and hyperkalemia predict cardiovascular risk during blood pressure lowering therapy in patients with diabetes and nephropathy [abstract no: SA-PO2407]","volume":"21","author":"Lambers Heerspink","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2013.09.016","article-title":"Estimated GFR decline as a surrogate end point for kidney failure: A post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)","volume":"63","author":"Lambers Heerspink","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/ndt\/gfh408","article-title":"The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy","volume":"19","author":"Leung","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0362|cit362","first-page":"788","article-title":"Losartan and the kidney protection. The RENAAL study","volume":"92","year":"2001","journal-title":"Recenti Progressi in Medicina"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1053\/j.ajkd.2014.06.008","article-title":"Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial","volume":"64","author":"McMullan","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial [Erratum appears in Diabetologia. 2011 Aug;54(8):2209]","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0365|cit365","first-page":"738A","article-title":"Serum potassium and renal outcomes in the RENAAL trial [abstract no: SA-PO2742]","volume":"20","author":"Miao","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","article-title":"Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial","volume":"58","author":"Miao","year":"2011","journal-title":"Hypertension"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0367|cit367","first-page":"399A","article-title":"Baseline hemoglobin predicts decline in renal function in patients with Type 2 diabetes and nephropathy [abstract no: SA-PO468]","volume":"14","author":"Mohanram","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0368|cit368","first-page":"455","article-title":"Distribution of hemoglobin concentration in patients with Type 2 diabetes and nephropathy [abstract no: SA-PO721]","volume":"14","author":"Mohanram","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006257.pub2-BIB0369|cit369","first-page":"8A","article-title":"Anemia is an independent risk factor for progression to end-stage renal disease (ESRD) in type 2 diabetics with nephropathy: results from the reduction in endpoints in non-insulin dependent diabetes mellitus with the angiotensin II antagonist losartan (RENAAL) trial [abstract no: F-FC034]","volume":"13","author":"Mohanram","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1523-1755.2004.00863.x","article-title":"Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy","volume":"66","author":"Mohanram","year":"2004","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/sj.ki.5002746","article-title":"The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes","volume":"73","author":"Mohanram","year":"2008","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0372|cit372","first-page":"553A","article-title":"The renoprotective effect of angiotensin II receptor blockade in Type 2 diabetics with nephropathy and impact on anemia [abstract no: F-PO993]","volume":"16","author":"Mohanram","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0373|cit373","first-page":"552A","article-title":"Association between changes in serum uric acid and renoprotection in the RENAAL trial [abstract no: F-PO1927]","volume":"21","author":"Ottenbros","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"40","key":"10.1002\/14651858.CD006257.pub2-BIB0374|cit374","first-page":"5514","article-title":"Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy","volume":"163","author":"Parving","year":"2001","journal-title":"Ugeskrift for Laeger"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1681\/ASN.2007050582","article-title":"ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy","volume":"19","author":"Parving","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1097\/01.ASN.0000146423.71226.0C","article-title":"Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results","volume":"15","author":"Remuzzi","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006257.pub2-BIB0377|cit377","first-page":"S158","article-title":"New aspects in renal protection by angiotensin receptor antagonists: the RENAAL study [abstract no: V3-3]","volume":"126","author":"Risler","year":"2001","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.ajkd.2015.03.032","article-title":"Serum bicarbonate and kidney disease progression and cardiovascular outcome in patients with diabetic nephropathy: a post hoc analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)","volume":"66","author":"Schutte","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1440-1797.2005.00472.x","article-title":"Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective","volume":"10","author":"Seng","year":"2005","journal-title":"Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0380|cit380","first-page":"603A","article-title":"Serum creatinine and risk for cardiovascular events in patients with diabetes: RENAAL and LIFE [abstract no: SU-PO314]","volume":"14","author":"Shahinfar","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006257.pub2-BIB0381|cit381","first-page":"105","article-title":"Losartan treatment effect on renal outcomes in type 2 diabetic patients with nephropathy after adjusting for an imbalance in baseline proteinuria [abstract no: M336]","volume":"18","author":"Shahinfar","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1046\/j.1523-1755.62.s82.13.x","article-title":"Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study","volume":"82","author":"Shahinfar","year":"2002","journal-title":"Kidney International - Supplement"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0383|cit383","first-page":"682A","article-title":"The importance of baseline distribution of proteinuria in renal outcomes trials: lessons from RENAAL [abstract no: SU-PO674]","volume":"14","author":"Shahinfar","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0384|cit384","first-page":"682A","article-title":"The albumin\/creatine ratio and 24 hour proteinuria excretion have similar predictive power for renal endpoints in diabetic nephropathy [abstract no: SU-PO675]","volume":"14","author":"Shahinfar","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0385|cit385","first-page":"601A","article-title":"The impact of blood pressure on the anti-proteinuric effect of losartan in Type II diabetes [abstract no: SU-PO308]","volume":"14","author":"Shahinfar","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/HJH.0b013e32835200f9","article-title":"An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials","volume":"30","author":"Smink","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1262-3636(07)70004-6","article-title":"An economic evaluation of losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France","volume":"29","author":"Souchet","year":"2003","journal-title":"Diabetes & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11892-003-0011-3","article-title":"Blood pressure and diabetic nephropathy","volume":"3","author":"Stanton","year":"2003","journal-title":"Current Diabetes Reports"},{"issue":"31-32","key":"10.1002\/14651858.CD006257.pub2-BIB0389|cit389","first-page":"440","article-title":"The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study","volume":"134","author":"Szucs","year":"2004","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0390|cit390","first-page":"766A","article-title":"Effect of LDL-cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study [abstract no: SA-PO956]","volume":"16","author":"Tershakovec","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2337\/dc07-0196","article-title":"Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study","volume":"31","author":"Tershakovec","year":"2008","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.2337\/dc06-0570","article-title":"Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes","volume":"29","author":"Winkelmayer","year":"2006","journal-title":"Diabetes Care"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006257.pub2-BIB0393|cit393","first-page":"429A","article-title":"Losartan reduced the costs associated with ESRD: implications from the RENAAL study for Singapore General Hospital [abstract no: SAP0802]","volume":"13","author":"Wong","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1681\/ASN.2004080632","article-title":"Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study","volume":"16","author":"Zhang","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0395|cit395","first-page":"174","article-title":"Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA","volume":"33","author":"Portu","year":"2011","journal-title":"Clinical & Experimental Hypertension (New York)"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"Zeeuw","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"Zeeuw","year":"2004","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.HYP.0000153308.91043.97","article-title":"Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus","volume":"45","author":"Rizzoni","year":"2005","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.16.4.597","article-title":"Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors","volume":"16","author":"Romero","year":"1993","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"e1003691","DOI":"10.1371\/journal.pmed.1003691","article-title":"Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: a prospective, randomized, open-label, blinded endpoint (PROBE) study","volume":"18","author":"Ruggenenti","year":"2021","journal-title":"PLoS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/dom.13639","article-title":"Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial","volume":"21","author":"Ruggenenti","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/(SICI)1096-9136(199602)13:2<120::AID-DIA6>3.0.CO;2-F","article-title":"Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study","volume":"13","author":"Sano","year":"1996","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/diacare.17.5.420","article-title":"Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients","volume":"17","author":"Sano","year":"1994","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10157-003-0227-1","article-title":"Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy","volume":"7","author":"Sato","year":"2003","journal-title":"Clinical & Experimental Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabres.2007.08.004","article-title":"A renoprotective effect of low dose losartan in patients with type 2 diabetes","volume":"79","author":"Sawaki","year":"2008","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.jhh.1001812","article-title":"Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial","volume":"19","author":"Schram","year":"2005","journal-title":"Journal of Human Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.diabres.2005.06.010","article-title":"Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension","volume":"71","author":"Sengul","year":"2006","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"Supramaximal dose of candesartan in proteinuric renal disease","volume":"20","author":"Burgess","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0409|cit409","first-page":"57A","article-title":"A double-blind randomized controlled trial of high dose candesartan cilexetil in proteinuric renal disease - results from SMART (Supra Maximal Atacand Renal Trial) [abstract no: SA-FC104]","volume":"18","author":"Burgess","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006257.pub2-BIB0410|cit410","first-page":"357","article-title":"A randomised controlled trial of high dose candesartan in the treatment of proteinuric renal disease: design and baseline characteristics [abstract no: SA-PO261]","volume":"15","author":"Muirhead","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD006257.pub2-BIB0411|cit411","first-page":"137A","article-title":"Anemia and renal insufficiency as risk factors for mortality in patients with left ventricular dysfunction [abstract no: A0739]","volume":"11","author":"Al-Ahmad","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0412|cit412","first-page":"152A","article-title":"Level of renal function as an independent predictor of mortality in patients with left ventricular dysfunction [abstract no: A0783]","volume":"10","author":"Al-Ahmad","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ahj.2010.09.020","article-title":"Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease","volume":"161","author":"Alsheikh-Ali","year":"2011","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0414|cit414","first-page":"322A","article-title":"Anemia as a risk factor for kidney function decline in heart failure [abstract no: TH-PO928]","volume":"16","author":"Bansal","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.amjcard.2006.11.055","article-title":"Anemia as a risk factor for kidney function decline in individuals with heart failure","volume":"99","author":"Bansal","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0416|cit416","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2337\/diacare.23.3.377","article-title":"Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction","volume":"23","author":"Capes","year":"2000","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjcard.2003.08.011","article-title":"Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction","volume":"92","author":"Gregory","year":"2003","journal-title":"American Journal of Cardiology"},{"issue":"5 (Pt 1)","key":"10.1002\/14651858.CD006257.pub2-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-8703(99)70009-8","article-title":"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)","volume":"138","author":"Knight","year":"1999","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2019.05.019","article-title":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction","volume":"96","author":"McCallum","year":"2019","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0421|cit421","first-page":"464","article-title":"Kidney function outcomes following RAAS inhibition in patients with heart failure [abstract no: FR-PO175]","volume":"29","author":"McCallum","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0422|cit422","first-page":"43","article-title":"Mortality outcomes related to acute declines in eGFR following RAAS inhibition in patients with heart failure [abstract no: FR-OR016]","volume":"29","author":"McCallum","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0423|cit423","first-page":"211","article-title":"Quality of life in women with heart failure, normative groups, and patients with other chronic conditions","volume":"11","author":"Riedinger","year":"2002","journal-title":"American Journal of Critical Care"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0424|cit424","first-page":"315","article-title":"Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction [Erratum in: Am J Cardiol 1990 Oct 15;66(12):1026]","volume":"66","year":"1990","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0425|cit425","first-page":"685","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circulation: Heart Failure"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0426|cit426","first-page":"685","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [Erratum in: N Engl J Med 1992 Dec 10;327(24):1768]","volume":"327","author":"Yusuf","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1097\/00004872-198812040-00146","article-title":"Angiotensin converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria","volume":"6","author":"Stornello","year":"1988","journal-title":"Journal of Hypertension - Supplement"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1097\/00004872-198900076-00153","article-title":"Angiotensin converting enzyme inhibition in normotensive type II diabetics with persistent mild proteinuria","volume":"7","author":"Stornello","year":"1989","journal-title":"Journal of Hypertension - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/dmrr.255","article-title":"Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria","volume":"18","author":"Tan","year":"2002","journal-title":"Diabetes\/Metabolism Research Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11306-018-1337-9","article-title":"1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics","volume":"14","author":"Tavares","year":"2018","journal-title":"Metabolomics"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0432|cit432","unstructured":"Titan S Barros R Zatz R Urinary biomarkers and prediction of proteinuria progression in diabetic nephropathy [abstract no: M327] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006257.pub2-BIB0433|cit433","first-page":"28A","article-title":"The effect of enalapril and losartan association therapy on proteinuria progression in advanced diabetic nephropathy: a double-blind randomized clinical trial [abstract no: TH-FC129]","volume":"19","author":"Titan","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0434|cit434","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5414\/CN107013","article-title":"ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial","volume":"76","author":"Titan","year":"2011","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jdiacomp.2012.06.006","article-title":"Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy","volume":"26","author":"Titan","year":"2012","journal-title":"Journal of Diabetes & its Complications"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2215\/CJN.04250510","article-title":"FGF-23 as a predictor of renal outcome in diabetic nephropathy","volume":"6","author":"Titan","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1463-1326.2005.00514.x","article-title":"The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency","volume":"8","author":"Tong","year":"2006","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","article-title":"Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies","volume":"10","author":"Anderson","year":"2011","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2215\/CJN.06640712","article-title":"Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures","volume":"8","author":"Barzilay","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: The ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/dc11-0545","article-title":"Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study","volume":"34","author":"Barzilay","year":"2011","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCULATIONAHA.109.864199","article-title":"Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/TRANSCEND) Trials","volume":"121","author":"Bohm","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.diabres.2008.12.005","article-title":"Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET\/TRANSCEND research programme","volume":"83","author":"Cukierman-Yaffe","year":"2009","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"e13694","DOI":"10.1371\/journal.pone.0013694","article-title":"In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events","volume":"5","author":"Dans","year":"2010","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"23","key":"10.1002\/14651858.CD006257.pub2-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1161\/CIRCULATIONAHA.112.103234","article-title":"Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries","volume":"126","author":"Dehghan","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.106.661405","article-title":"Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk","volume":"115","author":"Held","year":"2007","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.111.086660","article-title":"Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)","volume":"126","author":"Kappert","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00392-013-0644-4","article-title":"Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET\/TRANSCEND","volume":"103","author":"Lonn","year":"2014","journal-title":"Clinical Research in Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/HJH.0000000000002567","article-title":"Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials","volume":"38","author":"Mancia","year":"2020","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0451|cit451","unstructured":"Mann J Schmieder R Dyal L Schumacher H Dagenais G Teo K Renal outcomes with telmisartan in 5926 people at high vascular risk, results of the TRANSCEND study, a randomised placebo controlled trial [abstract no: SA777] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"Mann","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0453|cit453","first-page":"707A","article-title":"A gene variant in the CERS2 gene is associated with worsening albuminuria in diabetic patients of ON TARGET and TRANSCEND [abstract no: SA-PO351]","volume":"24","author":"Shiffman","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","article-title":"Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials","volume":"148","author":"Teo","year":"2004","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0455|cit455","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/HJH.0b013e3283522a51","article-title":"Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies","volume":"30","author":"Verdecchia","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"14","key":"10.1002\/14651858.CD006257.pub2-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.109.865774","article-title":"Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease","volume":"120","author":"Verdecchia","year":"2009","journal-title":"Circulation"},{"issue":"9644","key":"10.1002\/14651858.CD006257.pub2-BIB0458|cit458","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial [Erratum in: Lancet. 2008 Oct 18;372(9647):1384]","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD006257.pub2-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0460|cit460","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/0895-7061(95)00162-I","article-title":"Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group","volume":"8","author":"Trevisan","year":"1995","journal-title":"American Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0461|cit461","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s592-001-8073-2","article-title":"Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study","volume":"38","author":"Tutuncu","year":"2001","journal-title":"Acta Diabetologica"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.03350708","article-title":"Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)","volume":"4","author":"Fried","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0463|cit463","first-page":"1B","article-title":"Combined angiotensin inhibition for treatment of diabetic nephropathy: VA nephron D [abstract no: HI-OR03]","volume":"24","author":"Fried","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"20","key":"10.1002\/14651858.CD006257.pub2-BIB0464|cit464","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0465|cit465","first-page":"284","article-title":"ESRD and mortality after VA NEPHRON-D [abstract no: TH-PO717]","volume":"28","author":"Fried","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0466|cit466","first-page":"11","article-title":"Ascertaining study participant safety using centralized electronic medical records in a clinical trial setting - lessons learned from the veteran affairs NEPHRON-D trial [abstract no: P27]","volume":"18","author":"Huang","year":"2017","journal-title":"Trials"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0467|cit467","first-page":"11A","article-title":"Blood pressure and renal outcomes in diabetic kidney disease: results from the VA NEPHRON-D trial [abstract no: TH-OR037]","volume":"26","author":"Leehey","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0468|cit468","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2215\/CJN.02850315","article-title":"BP and renal outcomes in diabetic kidney disease: The Veterans Affairs Nephropathy in Diabetes Trial","volume":"10","author":"Leehey","year":"2015","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0469|cit469","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2215\/CJN.03470316","article-title":"Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade","volume":"11","author":"Palevsky","year":"2016","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0470|cit470","first-page":"5B","article-title":"Risk and severity of hyperkalemia with combined angiotensin antagonism in diabetic nephropathy- the VA-NEPHRON-D study [abstract no: SA-PO1089]","volume":"24","author":"Seliger","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0471|cit471","first-page":"466","article-title":"Titration management of study drugs in the VA NEPHRON-D trial [abstract no: P34]","volume":"7","author":"Zhang","year":"2010","journal-title":"Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0472|cit472","first-page":"385","article-title":"Secondary prevention of diabetic nephropathy by captopril in patients with insulin-dependent diabetes mellitus (IDDM) and microalbuminuria [abstract no: 119P]","volume":"5","author":"Viberti","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0473|cit473","unstructured":"Viverti GC Microalbuminuria Captopril Study Group Treatment of normotensive microalbuminuric IDDM patients [abstract] 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 66"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0474|cit474","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1191\/1358863x05vm608oa","article-title":"ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study","volume":"10 Suppl 1","author":"Boger","year":"2005","journal-title":"Vascular Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0475|cit475","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1093\/ndt\/gfn230","article-title":"Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy","volume":"23","author":"Galle","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0476|cit476","unstructured":"VIVALDI: A trial to investigate the efficacy of telmisartan 80mg versus valsartan 160mg in hypertensive type-2 diabetic patients with overt nephropathy The Protection Trial Programme - Micardis Protection 2005"},{"issue":"21","key":"10.1002\/14651858.CD006257.pub2-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"e130317","DOI":"10.1172\/jci.insight.130317","article-title":"Increased lipogenesis and impaired beta-oxidation predict type 2 diabetic kidney disease progression in American Indians","volume":"4","author":"Afshinnia","year":"2019","journal-title":"JCI insight"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2018111166","article-title":"Changes in albuminuria but not GFR are associated with early changes in kidney structure in type 2 diabetes","volume":"30","author":"Looker","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0479|cit479","first-page":"A140","article-title":"Long-term effect of losartan on kidney disease in American Indians with type 2 diabetes [abstract no: 536-P]","volume":"65","author":"Tanamas","year":"2016","journal-title":"Diabetes"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2337\/dc16-0795","article-title":"Long-term effect of losartan on kidney disease in American Indians with type 2 diabetes: a follow-up analysis of a randomized clinical trial","volume":"39","author":"Tanamas","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.2337\/db12-1512","article-title":"Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes","volume":"62","author":"Weil","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0482|cit482","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ki.2012.234","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy","volume":"82","author":"Weil","year":"2012","journal-title":"Kidney International"},{"issue":"Sept","key":"10.1002\/14651858.CD006257.pub2-BIB0483|cit483","first-page":"124A","article-title":"Interstitial volume changes, but not glomerulopathy, are limited by angiotensin converting enzyme inhibition after 2 years of therapy in type 2 diabetic patients with nephropathy [abstract no: A0668]","volume":"11","author":"White","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1464-5491.2001.00607.x","article-title":"Does ACE inhibition slow progression of glomerulopathy in patients with Type 2 diabetes mellitus?","volume":"18","author":"White","year":"2001","journal-title":"Diabetic Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0485|cit485","first-page":"533","article-title":"Protective effect of angiotensin converting enzyme inhibitor on renal function in normotensive non-insulin dependent diabetes mellitus patients with early diabetic nephropathy and microalbuminuria","volume":"35","author":"Xia","year":"1996","journal-title":"Chung-Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0486|cit486","first-page":"826","article-title":"The effect of perindopril in treatment of early diabetic nephropathy with normal blood pressure and microalbuminuria","volume":"40","author":"Yao","year":"2001","journal-title":"Chung-Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0487|cit487","unstructured":"Yoldi A Llorente I Monreal M Diez J Salvador J Is the suppression of growth hormone involved in the kidney-protecting effects of captopril in patients with diabetic nephropathy? [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 198"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.amjhyper.2007.09.001","article-title":"Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus","volume":"20","author":"Yoneda","year":"2007","journal-title":"American Journal of Hypertension"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/BF03343901","article-title":"Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects","volume":"24","author":"Acbay","year":"2001","journal-title":"Journal of Endocrinological Investigation"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0490|cit490","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/ajkd.2002.31392","article-title":"Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels","volume":"39","author":"Agarwal","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0491|cit491","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1046\/j.1523-1755.2001.00745.x","article-title":"Add-on angiotensin receptor blockade with maximized ACE inhibition","volume":"59","author":"Agarwal","year":"2001","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0492|cit492","doi-asserted-by":"crossref","first-page":"F863","DOI":"10.1152\/ajprenal.00385.2002","article-title":"Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade","volume":"284","author":"Agarwal","year":"2003","journal-title":"American Journal of Physiology - Renal Physiology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0493|cit493","first-page":"118","article-title":"Study of ramipril, losartan and benazapril efficacy on microalbuminuria [abstract no: CNP 17]","volume":"11","author":"Alam","year":"2001","journal-title":"Indian Journal of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0494|cit494","first-page":"125A","article-title":"Angiotensin II receptor blockade and barrier function in diabetic nephropathy [abstract no: A0642]","volume":"10","author":"Andersen","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0495|cit495","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0496|cit496","first-page":"132A","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy [abstract no: A0679]","volume":"10","author":"Parving","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0497|cit497","first-page":"68A","article-title":"Differential effects of valsartan (V) and lisinopril (L) on potassium [K+] homeostasis in hypertensive patients with nephropathy [abstract no: A0349]","volume":"10","author":"Bakris","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney International"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD006257.pub2-BIB0499|cit499","first-page":"225","article-title":"Combination of enalapril and losartan therapy in diabetic nephropathy [abstract no: T129]","volume":"17","author":"Cetinkaya","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1368-5031.2004.00004.x","article-title":"Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes","volume":"58","author":"Cetinkaya","year":"2004","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000169075","article-title":"Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus","volume":"17","author":"Chan","year":"1997","journal-title":"American Journal of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0502|cit502","first-page":"302","article-title":"Ramipril (R) has antiproteinuric effect and maintains renal function in patients with type 1 diabetes mellitus (DM): a prospective double-blind dose finding trials (PRT) [abstract no: 39P]","volume":"4","author":"Chonko","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0503|cit503","first-page":"832","article-title":"Maintained autoregulation of glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients [abstract no: A4356]","volume":"12","author":"Christensen","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1046\/j.1523-1755.2001.00946.x","article-title":"Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients","volume":"60","author":"Christensen","year":"2001","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1479164112447310","article-title":"The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study","volume":"9","author":"Daikuhara","year":"2012","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0506|cit506","first-page":"602A","article-title":"Combining ACE inhibitors and angiotensin II receptor blockers to decrease proteinuria in patients with diabetic nephropathy [abstract no: SU-PO310]","volume":"14","author":"Dhillon","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0507|cit507","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials","volume":"151","author":"Bilous","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0508|cit508","unstructured":"Bilous RW Parving H Nishi C DIRECT-Renal: The effect of the angiotensive type 1 receptor blocker candesartan on the development of microalbuminuria in type 1 and type 2 diabetes [abstract no: LB-003] American Society of Nephrology (ASN) Renal Week; 2008 Nov 4-9; Philadelphia, PA 2008"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0509|cit509","first-page":"S99","article-title":"Renin angiotensin system blockade is effective in preventing microalbuminuria in hypertensive but not normotensive people with type 2 diabetes; further analysis of the DIRECT Programme [abstract no: 223]","volume":"53","author":"Bilous","year":"2010","journal-title":"Diabetologia"},{"issue":"9647","key":"10.1002\/14651858.CD006257.pub2-BIB0510|cit510","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0512|cit512","first-page":"499A","article-title":"Is urinary proteomics useful to predict retinopathy in type 2 diabetic patients in the DIRECT 2 study [abstract no: FR-PO607]","volume":"26","author":"Eickhoff","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0513|cit513","first-page":"1866","article-title":"Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study","volume":"32","author":"Lindhardt","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0514|cit514","first-page":"41A","article-title":"Urinary proteomics predict onset of microalbuminuria in a cohort of normoalbuminuric type 1 diabetic patients in the DIRECT 1 study [abstract no: FR-OR048]","volume":"23","author":"Lindhardt","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0515|cit515","first-page":"213A","article-title":"Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients in the DIRECT 2 study [abstract no: TH-PO507]","volume":"23","author":"Lindhardt","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9647","key":"10.1002\/14651858.CD006257.pub2-BIB0516|cit516","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial","volume":"372","author":"Sjolie","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0517|cit517","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics","volume":"6","author":"Sjolie","year":"2005","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"Suppl 1A","key":"10.1002\/14651858.CD006257.pub2-BIB0518|cit518","article-title":"Candesartan reduces vascular complications in type 2 diabetic patients without cardiovascular disease or microalbuminuria [abstract]","volume":"58","author":"Tillin","year":"2009","journal-title":"Diabetes"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0519|cit519","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1056\/NEJMc063077","article-title":"Effect of ramipril on the incidence of diabetes","volume":"356","author":"Bangalore","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD006257.pub2-BIB0520|cit520","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0521|cit521","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2337\/dc07-1868","article-title":"Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial","volume":"31","author":"Dagenais","year":"2008","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0522|cit522","first-page":"523","article-title":"Effect of ramipril on the incidence of diabetes","volume":"356","author":"Epstein","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"9541","key":"10.1002\/14651858.CD006257.pub2-BIB0523|cit523","first-page":"1096","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [Erratum in: Lancet. 2006 Nov 18;368(9549):1770]","volume":"368","author":"Gerstein","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0524|cit524","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00125-004-1485-5","article-title":"Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial","volume":"47","author":"Gerstein","year":"2004","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0525|cit525","first-page":"522","article-title":"Effect of ramipril on the incidence of diabetes","volume":"356","author":"Potter","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0526|cit526","unstructured":"Dreyling KW Grotz W Keller E Schollmeyer P Angiotensin converting enzyme (ACE) - inhibitors induce blood count changes in patients with diabetic nephropathy [abstract] 11th International Congress of Nephrology 1990 160A"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0527|cit527","first-page":"189","article-title":"Enalapril (E) in normotensive Type 1 diabetes (DM-1): a double blind cross-over study in patients with elevated glomerular filtration rate (GFR) and renal plasma flow (RPF) [abstract]","volume":"33","author":"Drummond","year":"1988","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0528|cit528","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00285294","article-title":"Enalapril does not alter renal function in normotensive, normoalbuminuric, hyperfiltering type 1 (insulin-dependent) diabetic children","volume":"32","author":"Drummond","year":"1989","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0529|cit529","unstructured":"Ekhlas Eid A Nguyen J Delcroix C Moutel M Esnault VL Effect of diuretics after dual blockade of renin-angiotensin-aldosterone system on severe proteinuria [abstract no: TO22] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 434 5"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0530|cit530","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1681\/ASN.2004060505","article-title":"Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents","volume":"16","author":"Esnault","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0531|cit531","first-page":"762A","article-title":"Angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) and diuretics for refractory proteinuria [abstract no: SU-PO1030]","volume":"14","author":"Esnault","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0532|cit532","unstructured":"Feasibility of aggressively lowering urine albumin in individuals with kidney biopsy-proven diabetic kidney disease - a pilot study https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-001661-21-DK"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006257.pub2-BIB0533|cit533","first-page":"v240","article-title":"Chronic angiotensin II receptor blockade reduces intra(renal) vascular resistance in patients with type 2 diabetes mellitus [abstract no: MP121]","volume":"20","author":"Fliser","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0534|cit534","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1681\/ASN.2004100852","article-title":"Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes","volume":"16","author":"Fliser","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0535|cit535","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000087211","article-title":"Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study","volume":"25","author":"Garg","year":"2005","journal-title":"American Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0536|cit536","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.diabres.2004.02.015","article-title":"Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy","volume":"66","author":"Haneda","year":"2004","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"6545","key":"10.1002\/14651858.CD006257.pub2-BIB0537|cit537","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/bmj.293.6545.467","article-title":"Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy","volume":"293","author":"Hommel","year":"1986","journal-title":"British Medical Journal Clinical Research Ed"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0538|cit538","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3329\/bmrcb.v35i2.2885","article-title":"Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients","volume":"35","author":"Hoque","year":"2009","journal-title":"Bangladesh Medical Research Council Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0539|cit539","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3892\/etm.2016.3933","article-title":"Effect of telmisartan and enalapril on ventricular remodeling and kidney prognosis of patients with coronary artery disease complicated with diabetic nephropathy","volume":"13","author":"Hou","year":"2017","journal-title":"Experimental & Therapeutic Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0540|cit540","doi-asserted-by":"crossref","first-page":"A71","DOI":"10.1046\/j.1440-1797.2000.005003a71.x","article-title":"A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract no: 17]","volume":"5","author":"Houlihan","year":"2000","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0541|cit541","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.2337\/diacare.25.6.1072","article-title":"Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction","volume":"25","author":"Houlihan","year":"2002","journal-title":"Diabetes Care"},{"issue":"Sept","key":"10.1002\/14651858.CD006257.pub2-BIB0542|cit542","first-page":"116A","article-title":"Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract no: A0624]","volume":"11","author":"Houlihan","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0543|cit543","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/diacare.25.4.663","article-title":"A low-sodium diet potentiates the effects of losartan in type 2 diabetes","volume":"25","author":"Houlihan","year":"2002","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0544|cit544","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1507\/endocrj.K06-025","article-title":"Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes","volume":"53","author":"Igarashi","year":"2006","journal-title":"Endocrine Journal"},{"issue":"Sept","key":"10.1002\/14651858.CD006257.pub2-BIB0545|cit545","first-page":"117A","article-title":"Losartan decreases TGF-b1 plasma levels and urinary albumin excretion in patients with diabetes type-II and microalbuminuria [abstract no: A0630]","volume":"11","author":"Inigo","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0546|cit546","first-page":"59","article-title":"Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy","volume":"64 Suppl 2","author":"Insua","year":"1988","journal-title":"Postgraduate Medical Journal"},{"issue":"Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0547|cit547","first-page":"A30","article-title":"Effect of renin angiotensin system inhibitors (ACEI) and blockers (ATRB) on proteinuria and blood pressure reduction in patients with diabetic nephropathy [abstract no: M-PO20059]","volume":"10","author":"Iqbal","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006257.pub2-BIB0548|cit548","first-page":"iv5","article-title":"Tolerance of high dose enalapril and losartan for proteinuria and blood pressure reduction in patients with chronic kidney disease [abstract no: SO008]","volume":"21","author":"Iqbal","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006257.pub2-BIB0549|cit549","first-page":"vi92","article-title":"Alterations in serum K+ level at different doses of enalapril and losartan for treating type 2 diabetic CKD patients [abstract no: FP219]","volume":"22","author":"Islam","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0550|cit550","first-page":"148A","article-title":"Dual blockade of the renin-angiotensin system in type 1 diabetic patients with diabetic nephropathy [abstract no: A0777]","volume":"12","author":"Jacobsen","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0551|cit551","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ndt\/17.6.1019","article-title":"Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy","volume":"17","author":"Jacobsen","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0552|cit552","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/ndt\/gfl012","article-title":"Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy","volume":"21","author":"Jacobsen","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0553|cit553","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy","volume":"14","author":"Jacobsen","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0554|cit554","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/ndt\/gfl012","article-title":"Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy","volume":"21","author":"Jacobsen","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0555|cit555","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney International"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0556|cit556","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/ndt\/gfl012","article-title":"Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy","volume":"21","author":"Jacobsen","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"17","key":"10.1002\/14651858.CD006257.pub2-BIB0557|cit557","doi-asserted-by":"crossref","first-page":"e29080","DOI":"10.1097\/MD.0000000000029080","article-title":"Effects of alpha lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: a protocol for a parallel, randomized, double-blind, controlled clinical trial","volume":"101","author":"Jiao","year":"2022","journal-title":"Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0558|cit558","doi-asserted-by":"crossref","first-page":"246","DOI":"10.7326\/0003-4819-118-4-199302150-00002","article-title":"Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor","volume":"118","author":"Keilani","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"20","key":"10.1002\/14651858.CD006257.pub2-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9149(93)91053-K","article-title":"Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril","volume":"72","author":"Schlueter","year":"1993","journal-title":"American Journal of Cardiology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0560|cit560","first-page":"75A","article-title":"Comparison of the effect of 50% increase in angiotensin converting enzyme inhibitor (ACEI) with a combination of candesartan and ACEI on proteinuria and blood pressure in chronic renal disease [abstract no: A0392]","volume":"12","author":"Kincaid-Smith","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006257.pub2-BIB0561|cit561","first-page":"A25","article-title":"Comparison of the effect of 50% increase in angiotensin converting enzyme inhibitor (ACEI) with a combination of candesartan and ACEI on proteinuria and blood pressure in chronic renal disease [abstract no: P99]","volume":"7","author":"Kincaid-Smith","year":"2002","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/ndt\/17.4.597","article-title":"Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria","volume":"17","author":"Kincaid-Smith","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006257.pub2-BIB0563|cit563","first-page":"131","article-title":"A fall in urine protein with combined angiotensin converting enzyme inhibitor (ACEI) and aII receptor antagonist (AIIRA) treatment predicts a good outcome at three years in patients with chronic renal disease with continuing reduction in urine protein levels. Diabetic and obese patients with a poor response to combined ACEI and AIIRA treatment have a poor outcome [abstract no: M419]","volume":"18","author":"Kincaid-Smith","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Sept","key":"10.1002\/14651858.CD006257.pub2-BIB0564|cit564","first-page":"349A","article-title":"Randomised controlled crossover study of the effect on proteinuria of adding an angiotensin 11-receptor antagonist (ARA) to an angiotensin converting enzyme inhibitor (ACEI) [abstract no: A1825]","volume":"11","author":"Kincaid-Smith","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0565|cit565","first-page":"786A","article-title":"A fall in urine protein with combined angiotensin converting enzyme inhibitor (ACEI) and AII receptor antagonist (AIIRA) treatment predicts a good outcome at three years in patients with chronic renal disease (mean serum creatinine level of 0.18 mmols\/litre mean urinary protein level of 2.3 grams\/24 hours). Diabetic and obese patients with poor response to combined ACEI and AIIRA treatment have a poor outcome [abstract no: PUB059]","volume":"14","author":"Kincaid-Smith","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0566|cit566","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1463-1326.2006.00623.x","article-title":"Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study","volume":"9","author":"Lim","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0567|cit567","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1470320313475905","article-title":"Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients","volume":"15","author":"Lim","year":"2014","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0568|cit568","doi-asserted-by":"crossref","first-page":"e057503","DOI":"10.1136\/bmjopen-2021-057503","article-title":"Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: morphCKD","volume":"12","author":"M\u00e5rup","year":"2022","journal-title":"BMJ open"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0569|cit569","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/hr.2009.131","article-title":"Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy","volume":"32","author":"Masuda","year":"2009","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0570|cit570","first-page":"e89","article-title":"Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure profile in hypertensive patients with overt diabetic nephropathy [abstract no: P295]","volume":"54","author":"Tamura","year":"2009","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0571|cit571","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/1056-8727(94)00026-K","article-title":"Possible effect of angiotensin-converting enzyme inhibition on glomerular charge selectivity","volume":"9","author":"Hansen","year":"1995","journal-title":"Journal of Diabetes & its Complications"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0572|cit572","unstructured":"Hansen PM Mathiesen ER Kofoed-Enevoldsen A Possible effect of angiotensin converting enzyme (ACE) inhibition on glomerular charge selectivity [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 425"},{"issue":"6794","key":"10.1002\/14651858.CD006257.pub2-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.303.6794.81","article-title":"Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria","volume":"303","author":"Mathiesen","year":"1991","journal-title":"BMJ"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0574|cit574","first-page":"115A","article-title":"Preservation of normal GFR with long term captopril treatment in normotensive IDDM patients with microalbuminuria [abstract no: A0546]","volume":"8","author":"Mathiesen","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7201","key":"10.1002\/14651858.CD006257.pub2-BIB0575|cit575","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","article-title":"Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria","volume":"319","author":"Mathiesen","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0576|cit576","first-page":"452","article-title":"Efficacy of captopril in normotensive diabetic patients with microalbuminuria - 8 years follow-up [abstract no: 670]","volume":"6","author":"Mathiesen","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5414\/CNP64180","article-title":"Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy","volume":"64","author":"Matos","year":"2005","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0578|cit578","unstructured":"de Matos JP de Lourdes Rodrigues M Valenca D Ismerim V Boasquevisque E Barroso S Dual blockade of the renin-angiotensin system reduces plasma aldosterone, proteinuria and urinary tgb-b1 in type 2 diabetic patients with nephropathy [abstract no: MP135] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 275"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006257.pub2-BIB0579|cit579","first-page":"543A","article-title":"Antiproteinuric effect of losartan: is a higher dose as effective as an association with an ACE inhibitor? Results of a randomised triple-crossover study in proteinuric patients [abstract no: F-PO1920]","volume":"19","author":"Meier","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006257.pub2-BIB0580|cit580","first-page":"617A","article-title":"Comparative 24h blood pressure effects of increasing doses of losartan and the association of losartan and an ACE inhibitor in proteinuric patients [abstract no: SA-PO2249]","volume":"19","author":"Meier","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0581|cit581","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/HJH.0b013e328346d5dc","article-title":"Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study","volume":"29","author":"Meier","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0582|cit582","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/00004872-198811000-00011","article-title":"Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy","volume":"6","author":"Mimran","year":"1988","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0583|cit583","unstructured":"Antialbuminuric effects of valsartan and lisinopril www.clinicaltrials.gov\/ct\/show\/NCT00171600"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0584|cit584","unstructured":"Higher dose of ramipril versus addition of telmisartan-ramipril in hypertension and diabetes www.clinicaltrials.gov\/ct2\/show\/NCT00208221"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0585|cit585","unstructured":"Renohemodynamic Effects of Combined empagliflOzin and LosARtan (RECOLAR) www.clinicaltrials.gov\/show\/NCT04238702"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0586|cit586","unstructured":"Effect of olmesartan on angiotensin(1-7) levels and vascular functions in diabetes and hypertension (Ang(1-7)) www.clinicaltrials.gov\/show\/NCT05189015"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0587|cit587","unstructured":"Efficacy and safety of SPH3127 tablets on treating the diabetic kidney disease www.clinicaltrials.gov\/show\/NCT05593575"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0588|cit588","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s001250050891","article-title":"Renal autoregulation is normal in newly diagnosed, normotensive, NIDDM patients","volume":"41","author":"New","year":"1998","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0589|cit589","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/jhh.2011.22","article-title":"Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria","volume":"26","author":"Okura","year":"2012","journal-title":"Journal of Human Hypertension"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0590|cit590","first-page":"153A","article-title":"Relative renoprotective effect of ACE inhibitors (ACEi), angiotensin II antagonists (ATA), ACEi and ATA combination and dihydrophyridine calcium channel blockers (dCCBs) in overt nephropathy of type 2 diabetes [abstract]","volume":"12","author":"Parvanova","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0591|cit591","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/ki.1992.135","article-title":"Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy","volume":"41","author":"Pedersen","year":"1992","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0592|cit592","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.diabres.2012.11.004","article-title":"Blockade of the renin-angiotensin system and renal tissue oxygenation as measured with BOLD-MRI in patients with type 2 diabetes","volume":"99","author":"Pruijm","year":"2013","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0593|cit593","first-page":"39","article-title":"Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus","volume":"6","author":"Rasi Hashemi","year":"2012","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"6669","key":"10.1002\/14651858.CD006257.pub2-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bmj.298.6669.284","article-title":"Short term effect of captopril on microalbuminuria induced by exercise in normotensive diabetics","volume":"298","author":"Romanelli","year":"1989","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0595|cit595","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.25.1.95","article-title":"Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study","volume":"25","author":"Rossing","year":"2002","journal-title":"Diabetes Care"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006257.pub2-BIB0596|cit596","first-page":"155A","article-title":"Dual blockade of the renin-angiotensin system in type 2 diabetic patients with diabetic nephropathy [abstract no: A0813]","volume":"12","author":"Rossing","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0597|cit597","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/diacare.26.1.150","article-title":"Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0598|cit598","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"issue":"Nov","key":"10.1002\/14651858.CD006257.pub2-BIB0599|cit599","first-page":"601A","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE-inhibitor in diabetic nephropathy [abstract no: SU-PO307]","volume":"14","author":"Rossing","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0600|cit600","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1523-1755.2005.00394.x","article-title":"Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0601|cit601","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/00365513.2011.645055","article-title":"The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP","volume":"72","author":"Nielsen","year":"2012","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0602|cit602","first-page":"S484","article-title":"Tubular damage in type 2 diabetic nephropathy: the effect of ultrahigh doses of irbesartan [abstract no: 1225]","volume":"53","author":"Nielsen","year":"2010","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0603|cit603","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00726-011-0857-7","article-title":"Effect of irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria","volume":"42","author":"Rabbani","year":"2012","journal-title":"Amino Acids"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0604|cit604","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney International"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0605|cit605","first-page":"585A","article-title":"Reduction of plasma N-terminal pro-brain natriuretic peptide by angiotensin II receptor blockade in type 2 diabetic patients with microalbuminuria [abstract no: SA-PO043]","volume":"17","author":"Rossing","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0606|cit606","first-page":"572A","article-title":"Effects of recommended and ultra high doses of irbesartan on biomarkers of inflammation and endothelial dysfunction in type 2 diabetic patients with microalbuminuria [abstract no: SA-PO1040]","volume":"18","author":"Rossing","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0607|cit607","first-page":"C86","article-title":"Short-term comparison on antiproteinuric effects of losartan and enalapril in children with insulin-dependent diabetes mellitus and nephropathy [abstract no: OPFC47]","volume":"19","author":"Saka","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0608|cit608","first-page":"470-7","article-title":"Effect of lisinopril and verapamil on angiopoietin 2 and endostatin in hypertensive diabetic patients with nephropathy: a randomized trial","volume":"53","author":"Salem","year":"2021","journal-title":"Hormone & Metabolic Research"},{"issue":"11","key":"10.1002\/14651858.CD006257.pub2-BIB0609|cit609","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2337\/diacare.25.11.1909","article-title":"Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study","volume":"25","author":"Sasso","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0610|cit610","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-2005-861359","article-title":"Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone","volume":"37 Suppl 1","author":"Schjoedt","year":"2005","journal-title":"Hormone & Metabolic Research"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0611|cit611","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1464-5491.2010.03083.x","article-title":"Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril","volume":"27","author":"Nielsen","year":"2010","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0612|cit612","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00125-008-1184-8","article-title":"Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial","volume":"52","author":"Schjoedt","year":"2009","journal-title":"Diabetologia"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0613|cit613","first-page":"572A","article-title":"Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy [abstract no: SA-PO1041]","volume":"18","author":"Schjoedt","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006257.pub2-BIB0614|cit614","first-page":"133","article-title":"The effect of treatment with ultra high dose candesartan (64mg) on proteinuria: Interim results of a double-blind, randomized, multi-center study [abstract no: M427]","volume":"18","author":"Fleischmann","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0615|cit615","first-page":"A244","article-title":"Additive effect of ultra high dose (64 mg) candesartan on proteinuria: a double blind randomized study [abstract no: W-PO20003]","volume":"10","author":"Schmieder","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006257.pub2-BIB0616|cit616","first-page":"v69","article-title":"Dose-response effect of angiotensin receptor blocker candesartan on proteinuria: a double blind, randomized study [abstract no: SP149]","volume":"20","author":"Schmieder","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD006257.pub2-BIB0617|cit617","first-page":"119A","article-title":"Additional antiproteinuric effect of ultra high dose (64mg) candesartan: a double blind, randomized study [abstract no: F-P0243]","volume":"15","author":"Schmieder","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0618|cit618","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","article-title":"Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study","volume":"16","author":"Schmieder","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0619|cit619","first-page":"63","article-title":"Comparing the effectiveness of lisinopril and losartan potassium in treatment of microalbuminurea in newly diagnosed type II diabetes mellitus","volume":"28","author":"Seher","year":"2017","journal-title":"Medical Forum Monthly"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0620|cit620","first-page":"596","article-title":"Comparative study of the effects of enalapril and losartan on glomerular size selectivity in patients with proteinuria with and without diabetes [abstract]","volume":"29","author":"Shand","year":"1999","journal-title":"Australian & New Zealand Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0621|cit621","first-page":"321","article-title":"Antihypertensive treatment and glomerular size selectivity in hypertensive patients with renal parenchymal disease and proteinuria","volume":"58","author":"Shand","year":"2002","journal-title":"Clinical Nephrology"},{"issue":"1-2 Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0622|cit622","first-page":"A8","article-title":"Comparative study of the effects of enalapril and losartan on glomerular size selectivity in patients with proteinuria [abstract no: 22]","volume":"5","author":"Shand","year":"2000","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0623|cit623","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1524-6175.2002.2041.x","article-title":"Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches","volume":"5","author":"Bakris","year":"2003","journal-title":"Journal of Clinical Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0624|cit624","first-page":"A33","article-title":"Benefits of BP control using ACE\/CCB in type 2 diabetics [abstract no: 91]","volume":"39","author":"Weir","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0625|cit625","first-page":"S378","article-title":"Clinical observation on benazepril treatment of non-insulin-dependent diabetes mellitus patients with diabetic nephropathy [abstract no: P1220]","volume":"3","author":"Shu","year":"1997","journal-title":"Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006257.pub2-BIB0626|cit626","first-page":"59A","article-title":"Renoprotective effect of dual blockade of renin-angiotensin system by the combination of ACE inhibitor and ATII receptor antagonist in hypertensive IgA nephropathy [abstract no: SU-FC071]","volume":"15","author":"Kim","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0627|cit627","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5414\/CNP60318","article-title":"The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy","volume":"60","author":"Song","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006257.pub2-BIB0628|cit628","first-page":"566A","article-title":"Effects of combination therapy of ACE inhibitor and ATII receptor blocker on proteinuria and renal TGF-b production in Type II overt diabetic nephropathy: a comparison with doubling dose of single therapies [abstract no: SU-PO154]","volume":"15","author":"Song","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0629|cit629","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ndt\/gfi310","article-title":"Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease","volume":"21","author":"Song","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD006257.pub2-BIB0630|cit630","first-page":"A30","article-title":"Renoprotective benefits of low-dose combination of ACE inhibitor and ATII receptor blocker in advanced stage of overt diabetic nephropathy [abstract no: M-PO20056]","volume":"10","author":"Song","year":"2005","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0631|cit631","doi-asserted-by":"crossref","first-page":"173-84","DOI":"10.1159\/000512365","article-title":"Stronger effect of azilsartan on reduction of proteinuria compared to candesartan in patients with CKD: a randomized crossover trial","volume":"46","author":"Suehiro","year":"2021","journal-title":"Kidney & Blood Pressure Research"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0632|cit632","first-page":"56","article-title":"Evaluation of dosing time-related anti-hypertensive efficacy of valsartan in patients with type 2 diabetes","volume":"33","author":"Suzuki","year":"2011","journal-title":"Clinical & Experimental Hypertension (New York)"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0633|cit633","first-page":"151","article-title":"Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy","volume":"51","author":"Tan","year":"2010","journal-title":"Singapore Medical Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006257.pub2-BIB0634|cit634","first-page":"A22","article-title":"Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in Type 2 - diabetes [abstract no: M-PO20027]","volume":"10","author":"Schmieder","year":"2005","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0635|cit635","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2337\/dc06-1551","article-title":"Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes","volume":"30","author":"Schmieder","year":"2007","journal-title":"Diabetes Care"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006257.pub2-BIB0636|cit636","first-page":"v242","article-title":"Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in type 2 diabetes [abstract no: MP127]","volume":"20","author":"Schmieder","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006257.pub2-BIB0637|cit637","first-page":"iv289","article-title":"Pathogenetic factors of atherosclerosis are disparately influenced by telmisartan and ramipril in Type 2 diabetes [abstract no: MO005]","volume":"21","author":"Schmieder","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006257.pub2-BIB0638|cit638","first-page":"33A","article-title":"Pathogenetic factors of atherosclerosis are disparately influenced by telmisartan and ramipril in type 2 diabetes [abstract no: TH-FC151]","volume":"17","author":"Schmieder","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0639|cit639","unstructured":"TRENDY: Telmisartan versus ramipril in renal endothelial dysfunction The Protection Trial Programme - Micardis Protection 2005"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0640|cit640","first-page":"4","article-title":"Proteinuria a target for reno-protection in hypertensive patients with type 2 diabetic nephropathy","volume":"19","author":"Turab","year":"2008","journal-title":"Medical Forum Monthly"},{"issue":"Oct","key":"10.1002\/14651858.CD006257.pub2-BIB0641|cit641","first-page":"571A","article-title":"Beneficial effect of dual blockade of the renin-angiotensin system (RAS) on urinary connective tissue growth factor (CTGF) in Type 2 diabetic patients with nephropathy [abstract no: SU-PO180]","volume":"15","author":"Nieuwenhoven","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0642|cit642","first-page":"671","article-title":"Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril","volume":"81","author":"Vongterapak","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0643|cit643","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2337\/diab.41.1.62","article-title":"Effect of angiotensin-converting enzyme inhibition on renal function and albuminuria in normotensive type I diabetic patients","volume":"41","author":"Wiegmann","year":"1992","journal-title":"Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD006257.pub2-BIB0644|cit644","doi-asserted-by":"crossref","first-page":"2170-6","DOI":"10.1093\/ckj\/sfab031","article-title":"Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD","volume":"14","author":"Wouda","year":"2021","journal-title":"Clinical Kidney Journal"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0645|cit645","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/0003-4819-139-2-200307150-00008","article-title":"Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial","volume":"139","author":"Zandbergen","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0646|cit646","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2265.2006.02449.x","article-title":"The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial","volume":"64","author":"Zandbergen","year":"2006","journal-title":"Clinical Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD006257.pub2-BIB0647|cit647","first-page":"7630","article-title":"Clinical observation of ACEI combined with ARB for treatment of diabetic nephropathy in elderly patients","volume":"12","author":"Zhang","year":"2019","journal-title":"International Journal of Clinical & Experimental Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006257.pub2-BIB0648|cit648","first-page":"A90","article-title":"The reduction in 24 h blood pressure and diminution of microalbuminuria in incipient diabetic nephropathy treated with ACEI during 2 years [abstract]","volume":"12","author":"Andrysiak-Mamos","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0649|cit649","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2215\/CJN.0000000000000333","article-title":"Associations of biomarkers of tubular injury and inflammation with biopsy features in type 1 diabetes","volume":"19","author":"Limonte","year":"2024","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0650|cit650","first-page":"108","article-title":"Progression of persistent microalbuminuria in hypertensive versus normotensive type 2 diabetic patients: a follow-up study [abstract no: CNO18]","volume":"10","author":"Vijay","year":"2000","journal-title":"Indian Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0651|cit651","first-page":"113-21","article-title":"A comparative study on the pleiotropic effects of Olmesartan and Telmisartan in hypertensive patients with type 2 diabetes mellitus: a randomized, prospective, open labelled, hospital based study","volume":"12","author":"Vineela","year":"2023","journal-title":"Journal of Krishna Institute of Medical Sciences University"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0652|cit652","unstructured":"Dual RAAS blockage in primary glomerular diseases https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2023\/05\/052593"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0653|cit653","unstructured":"Azilsartan in patients with diabetic kidney disease and hypertension https:\/\/clinicaltrials.gov\/show\/NCT05753696"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0654|cit654","unstructured":"Comparison of efficacy in renoprotection between Azilsartan medoxomil and Enalapril: a randomized, open-labeled controlled trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=TCTR20220426002"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0655|cit655","first-page":"S149","article-title":"Actions of angiotensin II on the renal microvasculature","volume":"10 Suppl 11","author":"Arendshorst","year":"1999","journal-title":"Journal of the American Society of Nephrology : JASN"},{"issue":"7","key":"10.1002\/14651858.CD006257.pub2-BIB0656|cit656","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/medicina55070382","article-title":"Antihypertensive treatment in diabetic kidney disease: the need for a patient-centered approach","volume":"55","author":"Bonino","year":"2019","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0657|cit657","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0658|cit658","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/dme.14107","article-title":"Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria","volume":"37","author":"Coleman","year":"2019","journal-title":"Diabetic Medicine"},{"issue":"24","key":"10.1002\/14651858.CD006257.pub2-BIB0659|cit659","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0660|cit660","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0661|cit661","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney International"},{"issue":"13","key":"10.1002\/14651858.CD006257.pub2-BIB0662|cit662","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7650","key":"10.1002\/14651858.CD006257.pub2-BIB0663|cit663","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0664|cit664","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD006257.pub2-BIB0665|cit665","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0666|cit666","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviewsof Interventions version 6.3 (updated February 2022), Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD006257.pub2-BIB0667|cit667","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [Erratum in: JAMA. 2014 May 7;311(17):1809]","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"13","key":"10.1002\/14651858.CD006257.pub2-BIB0668|cit668","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/heartjnl-2020-318060","article-title":"Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure","volume":"107","author":"Joshi","year":"2021","journal-title":"Heart"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0669|cit669","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2021","journal-title":"Kidney International Supplement"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0670|cit670","doi-asserted-by":"crossref","first-page":"e1001293","DOI":"10.1371\/journal.pmed.1001293","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis","volume":"9","author":"Lv","year":"2012","journal-title":"PLoS Medicine"},{"issue":"12","key":"10.1002\/14651858.CD006257.pub2-BIB0671|cit671","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004136.pub3","article-title":"Antihypertensive agents for preventing diabetic kidney disease","author":"Lv","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"13","key":"10.1002\/14651858.CD006257.pub2-BIB0672|cit672","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?","volume":"71","author":"Messerli","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0673|cit673","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/1056-8727(95)80036-E","article-title":"Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients","volume":"9","author":"Mogensen","year":"1995","journal-title":"Journal of Diabetes & its Complications"},{"issue":"5-6","key":"10.1002\/14651858.CD006257.pub2-BIB0674|cit674","first-page":"895","article-title":"Drug treatment for hypertensive patients in special situations: diabetes and hypertension","volume":"21","author":"Mogensen","year":"1999","journal-title":"Clinical & Experimental Hypertension (New York)"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0675|cit675","unstructured":"K\/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Guideline 11: use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in CKD https:\/\/kidneyfoundation.cachefly.net\/professionals\/KDOQI\/guidelines_bp\/guide_11.htm"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0676|cit676","doi-asserted-by":"crossref","first-page":"d1673","DOI":"10.1136\/bmj.d1673","article-title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension","volume":"342","author":"Ritter","year":"2011","journal-title":"BMJ"},{"issue":"15","key":"10.1002\/14651858.CD006257.pub2-BIB0677|cit677","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1056\/NEJM199910073411506","article-title":"Nephropathy in patients with type 2 diabetes mellitus","volume":"341","author":"Ritz","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0678|cit678","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0679|cit679","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available fromwww.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0680|cit680","unstructured":"Standardised Outcomes in Nephrology https:\/\/songinitiative.org\/"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0681|cit681","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2369-14-95","article-title":"The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the renal impairment in secondary care (RIISC) study; rationale and protocol","volume":"14","author":"Stringer","year":"2013","journal-title":"BMC Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006257.pub2-BIB0682|cit682","doi-asserted-by":"crossref","first-page":"130\u20135","DOI":"10.1093\/ckj\/sfx091","article-title":"Chronic kidney disease, kidney transplantation and oxidative stress: a new look to successful kidney transplantation","volume":"11","author":"Tabriziani","year":"2018","journal-title":"Clinical Kidney Journal"},{"key":"10.1002\/14651858.CD006257.pub2-BIB0683|cit683","article-title":"Chronic kidney disease","author":"Vaidya","year":"2022","journal-title":"StatPearls"},{"issue":"3","key":"10.1002\/14651858.CD006257.pub2-BIB0684|cit684","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1159\/000489913","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis","volume":"43","author":"Wang","year":"2018","journal-title":"Kidney & Blood Pressure Research"},{"issue":"2","key":"10.1002\/14651858.CD006257.pub2-BIB0685|cit685","first-page":"257\u201362","article-title":"Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center","volume":"10","author":"Yuan","year":"2017","journal-title":"Clinical Kidney Journal"},{"issue":"8","key":"10.1002\/14651858.CD006257.pub2-BIB0686|cit686","doi-asserted-by":"crossref","first-page":"797\u2013811","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non\u2011dialysis chronic kidney disease stages 3\u20135: a network meta\u2011analysis of randomised clinical trial","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"issue":"7470","key":"10.1002\/14651858.CD006257.pub2-BIB0687|cit687","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006257.pub2-BIB0688|cit688","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006257","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","author":"Strippoli","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:36:23Z","timestamp":1756899383000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006257.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":688,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006257.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}